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Abstract 
Prion diseases are a group of fatal neurodegenerative diseases associated with 
proteopathy occurring in humans and other mammals. The mechanism of prion 
replication is thought to be based on the induced misfolding of the host encoded prion 
protein and can be emulated in vitro by methodologies termed cell-free conversion 
(CFC) systems. Currently, the two most common implementation of CFC systems are 
the Protein Misfolding Cyclic Amplification (PMCA) reaction and the Real Time 
Quaking Induced Conversion (RT-QuIC) reaction. The overarching aim of this thesis 
is to describe and compare the human prion amplification in vitro by PMCA and RT-
QuIC and to extend the diagnostic applicability of the latter, which is currently 
employed for the diagnosis of sporadic Creutzfeldt-Jakob disease (sCJD). Therefore, 
in this thesis, PMCA and RT-QuIC differential amplification abilities were 
systematically investigated and, for the first time, PMCA and RT-QuIC reaction 
kinetics compared using a specifically defined set of conditions. In addition, the 
research performed in this thesis has shown that the sCJD cerebrospinal fluid and 
brain samples seed the conformational change of the full-length hamster recombinant 
prion protein in a similar way in RT-QuIC, and that the RT-QuIC analysis of sCJD 
urine samples is possible, however, it has low sensitivity and, therefore, a limited 
diagnostic potential. 
Lay summary 
Prions are the causative agent of prion diseases, a group of infectious 
neurodegenerative diseases affecting humans and other mammals. Prions are unique 
among infectious agents because, at variance with viruses and bacteria, they are able 
to replicate themselves without relying on DNA or RNA to store the information 
needed. Cell-free systems are methodologies that allow emulating prion replication in 
vitro. The two most commonly used prion replication cell-free systems are the PMCA 
 
reaction and the RT-QuIC reaction. These methods are powerful tools to study prion 
biology and have found application to aid prion disease diagnosis in humans.  In this 
thesis, with the aim of gaining insight into the molecular mechanism of prion 
replication, the PMCA and the RT-QuIC reactions are compared on the basis of their 
differential abilities in amplifying and detecting human prions. Moreover, the results of 
a biochemical characterization of the RT-QuIC reaction products is presented, as well 
as a study regarding the possibility of achieving prion disease diagnosis by the RT-
QuIC analysis of human urine samples.
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Chapter 1: General Introduction  
1.1 The “protein-only” hypothesis and the concept of prions 
In the late 1950s’, William J. Hadlow, an American veterinarian, had the chance to 
attend an exhibition at the Wellcome Medical Museum in London, illustrating the 
clinical and neuropathological features of a recently described neurodegenerative 
disease affecting an isolated human population in the Eastern Highlands of Papua 
New Guinea. This endemic condition, named “kuru” (shivering) by the natives, was 
showing similarities at a neuropathological, clinical, and epidemiological level with 
“scrapie”, a fatal transmissible disease of sheep and goats recognized in Europe for 
over 200 years. This observation lead Hadlow to suggest that kuru, as with scrapie, 
might be transmissible and that possibly kuru and scrapie were determined by a 
similar pathogen (Hadlow 1959). The transmissibility of kuru was demonstrated a few 
years later, by intracerebral inoculation of kuru brain homogenate (BH) to non-human 
primates (Gajdusek, Gibbs, and Alpers 1967), confirming Hadlow’s intuition. Based 
on these results, Creutzfeldt-Jakob disease (CJD), another human 
neurodegenerative disease with neuropathological similarities with kuru and scrapie, 
was experimentally inoculated into non-human primates showing that it was also 
transmissible (Gibbs et al. 1968). Notwithstanding the transmissibility and 
neuropathological similarities linking kuru, scrapie and CJD, the hypothesis regarding 
a similar aetiological agent proved to be difficult to investigate at that time.  
The adaptation of the natural scrapie agent to the common laboratory rodents 
(Chandler 1961) and chiefly the isolation of the scrapie strain 263K in Syrian hamsters 
(Kimberlin and Walker 1978) were key to further investigation of this issue. Indeed, 
the Syrian hamster adapted scrapie strain 263K, which produces high titres of 
infectivity in a relatively short time, made it easier to titre scrapie infectivity in biological 
samples and to more rapidly generate infectious material to be analysed. Data started 
 
17 
accumulating showing that semi-purified fractions prepared from brains of 263K-
infected Syrian hamster enriched for scrapie infectivity were enriched in proteins but 
not in nucleic acids, leading to speculate that the scrapie aetiological agent was 
entirely proteinaceous (Prusiner et al. 1980). Inactivation studies of the scrapie agent 
in semi-purified fractions suggested that it was also devoid of nucleic acids (Prusiner 
et al. 1981). Moving from these bases, Prusiner postulated the “protein-only” 
hypothesis, proposing the existence of a novel biological infectious entity, termed 
“prion”, composed mainly, if not entirely, of a hydrophobic protein. Consequently to 
the lack of nucleic acids, Prusiner also suggested that the prion was able to induce or 
template its own synthesis in order to replicate (Prusiner 1982). 
The initial scepticism around the protein-only hypothesis and the existence of prions 
was overturned by the accumulation of evidence backing Prusiner’s insight over time 
(Prusiner 1998; 2004). According to the current paradigm, the central molecular event 
in diseases like kuru, scrapie and CJD, classically identified as Transmissible 
Spongiform Encephalopathies (TSEs) and currently referred to as Prion Diseases 
(PrDs), is the conformational change that transforms the cellular form of the host 
encoded prion protein (PrPC), into a β-sheet rich, amyloidogenic, partially proteinase 
resistant, conformer referred to as PrP Scrapie (PrPSc). Once PrPSc is formed, or 
exogenously acquired, it induces the conformational shift of PrPC leading to 
precipitation of pathognomonic PrPSc aggregates.  Hence, PrPSc appears to be able 
to transfer structural information without relying on informational molecules such as 
DNA or RNA. 
The centrality of the host encoded PrPC to PrDs pathology, was further confirmed by 
the observation that genetically modified mice lacking PrPC, are resistant to prion 
disease transmission (Büeler et al. 1993; Sailer et al. 1994; Brandner et al. 1996; 
2002). The latter observation, together with the in vitro generation of infectious 
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preparations (i.e. synthetic prions) from bacterially expressed recombinant PrPC 
(rPrP) and minimal non-proteinaceous components, are among the strongest 
evidence in support of the protein-only hypothesis (Deleault et al. 2007; Legname et 
al. 2004; Colby et al. 2009; Wang et al. 2010; Barria et al. 2009). The study of synthetic 
prions also revealed that, under specific conditons, it is possible to separate prion 
ability to induce misfolding from the generation of infectivity (Noble and Supattapone 
2015). 
Notably, the generalization of the biological concept that prions, as proteins, are 
capable of storing and transferring structural information, without necessarily 
displaying infectious properties, has been highly influential. Specifically, a prion-like 
behaviour has been proposed to explain the spreading within the peripheral and 
Central Nervous System (CNS) of the protein α-synuclein, which aggregates 
constitute the distinctive neuropathological hallmark of Parkinson’s disease (PD), 
Lewy Body Dementia, and other ‘synucleinopathies’. Similarly, the aggregation and 
spreading of the tau protein (τ-protein) which can be observed in Alzheimer’s disease 
(AD) brains has been proposed to rely on a prion-like mechanism. In addition to 
pathological processes, a number of physiological and biological processes have also 
been proposed to follow the prion-like model  (Scheckel and Aguzzi 2018; Hafner-
Bratkovič 2017).  
1.2 Molecular and structural biology of prions 
In humans the gene PRNP, encoding for the prion protein, is expressed ubiquitously 
(including skin, kidney, urinary bladder and spleen) but at the highest level in the brain 
(https://www.ncbi.nlm.nih.gov/gene/5621). Both PRNP and its product are highly 
conserved throughout the mammalian taxon (http://www.ensembl.org/). PrPC is 
synthesized in the rough endoplasmic reticulum (RER) as a polypeptide chain of 253 
aminoacid residues in humans, 254 in Syrian hamster and mice, 264 in bovines (Bos 
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taurus) and 256 in sheep (Ovis aries). PrPC post-translational modifications include: 
the cleavage of an N-terminal signal peptide (residues 1-22, human numbering, 
UniProt database accession number P04156), the addition of two facultative N-linked 
oligosaccharide chains (at asparagine residues 181 and 197), the formation of a 
disulfide bond (between the cysteine residues at 189 and 214), the insertion of a 
glycosylphosphatidylinositol (GPI) anchor with the simultaneous removal of a C-
terminal signal peptide (residues 231-254). The facultative glycosylation at 
asparagine residues 181 and 197 results in mono-, di-, and un-glycosylated forms of 
PrPC present in cells at the same time. The GPI anchor is responsible for PrPC 
association with lipid-rafts at the plasma membrane (Stahl et al. 1990).  
Nuclear Magnetic Resonance (NMR) spectroscopy and X-ray crystallography studies 
on bacterially expressed rPrPs from hamster, human, and other mammals, showed 
that they have essentially the same conformation. While the N-terminal portion from 
residues 23 to 127 is largely unfolded in solution, the C-terminus(residues 128 to 230)  
has a well-defined secondary and tertiary structure and is often referred to as the 
globular domain (GD) (Wüthrich and Riek 2001; Rossetti and Carloni 2017; Zahn et 
al. 2000). The GD is characterised by three α-helices at residues 144-154, 173-194, 
and 200-228 (hereafter referred to as α1 α2 and α3 respectively). The single disulfide 
bond connects α2 and α3.  
As mentioned, the central molecular event in PrDs is the conformational change of 
PrPC into PrPSc. Misfolded PrPC may form small aggregates (i.e. oligomers) and 
eventually fibrillary, amyloid-like PrPSc forms that, because of their insolubility, 
eventually precipitate and can form amyloid plaques in the central nervous system 
(CNS). At variance with PrPC, PrPSc, due to its amyloid-like conformation, is partially 
resistant to protease digestion. The resolution of PrPSc structure has been hampered 
by its insolubility in non-denaturing detergents. Fourier Transform Infrared (FTIR) 
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spectroscopy and Circular Dichroism (CD) spectroscopy data have shown that PrPSc 
structure has a high β-sheet content while α-helices dominate PrPC conformation 
(Caughey et al. 1991; Pan et al. 1993). Currently, studies of rPrP fibrils by means of 
cryogenic Electron Microscopy (cryo-EM), X-ray diffraction and solid state NMR 
spectroscopy (ssNMR), have led to two competing models of the PrPSc fibrillar 
structure: the Parallel In-Register Intermolecular β-Sheet (PIRIBS), and the 4-rung β-
solenoid model (Baskakov et al. 2019; Wille and Requena 2018; Groveman et al. 
2014). A growing line of evidence, however, indicates that small, transient, and 
structurally heterogeneous oligomers of misfolded PrP, are the species responsible 
for prion infectivity and toxicity rather than PrPSc (Kayed et al., 2003; Silveira et al., 
2005; Campioni et al., 2010; Sang et al., 2019). 
The limited proteolysis in standardized conditions of samples known to contain PrPSc, 
or of fractions enriched for this component, yield a fragment usually referred to as 
protease resistant prion protein (PrPres). Specifically, PrPres is defined operationally as 
the fragment obtained following limited proteolysis of PrPSc with Proteinase K (PK) 
and detected by immunochemical assay, typically a western blot (WB), with PrP 
specific monoclonal antibodies (mAb). PrPres is composed of the C-terminal part of 
the PrP sequence spanning residues from ~90 to 230 (231 in hamster). Beside its 
historical importance for the identification of the scrapie agent (Bolton, Mckinley, and 
Prusiner 1982), PrPres, is currently acknowledged internationally as the 
immunochemically detectable, decisive hallmark, for diagnosis of PrDs in humans.  
The molecular characterization of PrPres from human and animal PrD biological 
samples, has shown that the position of the N-terminal cleavage site is not fixed. 
Namely, the limited proteolysis of PrPSc yields a limited number of major PrPres types 
(e.g. two, in humans and hamster), that are defined on the basis of the size of the un-
glycosylated PrPres as assessed by standardized WB analysis. It has been 
 
21 
hypothesized that such observable diversity is due to slightly different PrPSc 
conformations (i.e. isotypes) exposing different regions of the prion protein 
polypeptide chain to degradation by PK. Adding to this, the relative abundance of di- 
mono- and un-glycosylated forms (i.e. glycotype) and the size of the un-glycosylated 
PrPres (i.e. PrPres type) as assessed by standardize WB analysis, vary in correlation 
with the different phenotypes of PrDs. This process, in combination with the status of 
certain polymorphic codons on the prion protein gene, have been exploited to achieve 
a molecular classification of human forms as well as animal forms of PrDs (Parchi et 
al. 1999; Telling et al. 1996; Bessen and Marsh 1992; Biacabe et al. 2004; Parchi et 
al. 1996).  
The conformational heterogeneity of PrPSc isotypes, which can be inferred by the 
detection of PrPres types upon PK digestion, has also been hypothesised to be the 
molecular determinant of the prion strain phenomenon. The concept of prion strains 
arose from the observation of the existence of several distinct isolates of agents, from 
phenotypically different PrDs that, when passaged in inbred mice of the same prion 
protein genotype, show reproducible incubation time and patterns of neuropathology 
(Collinge et al. 1996; Collinge and Clarke 2007; Safar et al. 1998; Bishop, Will, and 
Manson 2010; Moda et al. 2012; Fraser and Dickinson 1973; Pattison and Millson 
1961). Similarly, minor differences in PrPC primary and secondary structures have 
been used to explain the molecular basis of the “species barrier” phenomenon, typical 
of PrDs. The concept of the species barrier arose from the observation that 
transmission of PrDs between xenogeneic hosts, is typically far less efficient than 
between syngeneic individuals (Scott et al. 1989; 1997; Crozet et al. 2001; Vilotte et 
al. 2001; Tessier and Lindquist 2007; Sigurdson et al. 2010; Collinge et al. 1995; 
Kocisko et al. 2006). Exceptions to the species barrier phenomenon, however, do 
exist. It has been reported that the primary transmission of certain animal and human 
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prion diseases, including CJD, to bank voles (Clethrionomys Glareolus), occurs 
without the loss of efficiency typically observed with other laboratory animals (Nonno 
et al. 2006; Di Bari et al. 2008; Watts et al. 2014). 
1.4 Models of PrP conversion  
The idea that the replication of the scrapie agent involved a process resembling 
crystal formation was firstly suggested by James Stanley Griffith in 1967 (Griffith 
1967). The autocatalytic formation of crystals can, indeed, be seen as analogous to 
the process of protein misfolding, aggregation and amyloid fibril formation that was 
integrated in the framework of the prion concept to explain prion replication without 
the aid of nucleic acids (Cohen et al. 1994; Prusiner 1998; Jarrett and Lansbury 1993; 
Prusiner et al. 1990).  
Two models for the prion replication mechanism were conceived based on 
experimental evidence: the autocatalysis mechanism, usually referred to as 
Template-Assisted Model (TAM, Prusiner et al., 1990), and the nucleation-dependent 
polymerization or Nucleation-Polymerization Model (NPM, Jarrett and Lansbury, 
1993). The TAM postulates a low rate of production of PrPSc by spontaneous 
conversion of PrPC. The newly formed PrPSc then catalyses the conformational 
change of PrPC by direct contact (i.e. by forming a heterodimer), which in turn 
dissociate at a faster rate into two molecules of PrPSc. The mathematical description 
of this model, however, showed that unrealistic high values for the rate constants were 
required (Eigen 1996). Namely, this model does not accommodate the long incubation 
period typical of PrDs. In the same work, however, a simulation of the NPM model 
was given, showing that it had a higher potential to describe the characteristics of 
prion replication. 
In the NPM, conversion is initiated when oligomers of misfolded PrPC act as nuclei for 
the incorporation and conversion of PrPc into growing polymers of PrPSc. The 
 
23 
fragmentation of these fibril polymers provides nuclei for further polymerisation. The 
NPM is characterized by four key aspects: i) a threshold of nuclei size below which 
no replication occurs, ii) a lag-time before polymerization for nuclei just above the 
critical threshold, iii) a relatively rapid polymerisation for nuclei above the critical size, 
iv)a slow nucleation process that can be accelerated by the introduction of exogenous 
nuclei or “seeds”. The mathematical formalisation of the NPM describes in a more 
realistic way that, when PrP aggregates of a certain size are formed (i.e. oligomers), 
they can either elongate by the incorporation of a PrPC monomer or break into new 
aggregates (Nowak et al. 1998).  Further modification to the NPM formulation by 
Nowak and collaborators facilitated the validation of this model with in vitro data 
(Masel, Jansen and Nowak, 1999). Notwithstanding the progress made in the 
mathematical modelling of prion replication and in the broader research field of protein 
misfolding aggregation, to which the modelling of prion replication is integral (Dobson 
2003; Walker and LeVine 2003), a gap still exists with the in vitro experimental 
observations (Giehm and Otzen 2010). This can be ascribed to the technological 
hurdles posed by the direct observation of transient molecular events in chemically 
crowded environments such as the one typical of biological systems. In a recent 
publication, Sang and colleagues (Sang et al., 2019), reported the direct observation 
of mouse recombinant prion protein oligomer formation in vitro using Total Internal 
Reflection Fluorescence Microscopy (TIRFM) and spectrally-resolved Points 
Accumulation for Imaging in Nanoscale Topography (sPAINT). These methodologies 
might be the key for further elucidating the prion replication mechanism as well as the 
misfolding of other pathologically relevant proteins. 
1.5 Prion diseases 
Prion diseases (PrDs) or Transmissible spongiform encephalopathies (TSEs) are a 
group of fatal neurodegenerative diseases associated with proteopathy, affecting 
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humans and other mammals. PrDs may have sporadic or genetic aetiology but PrDs 
are also transmissible and hence can be exogenously acquired. The following 
paragraphs present a general description of human PrDs focussing on certain forms 
that presented the subjects of the experimental work in this thesis. Next, a brief 
description of the current criteria and methods for the clinical diagnosis of human PrDs 
is given. 
1.5.1 Human prion diseases 
As a group, human PrDs are rare diseases of middle aged and elderly people with a 
wide spectrum of clinical phenotypes. Based on the aetiology, clinical signs and 
neuropathology, distinct human PrDs are now recognised. Sporadic Creutzfeldt-
Jakob disease (sCJD) (i.e. idiopathic, unknown cause) is the most common form 
accounting for ~85% of all PrD cases. Genetic forms are due to point or insertional 
mutation in the PRNP gene and represent ~10% of all PrD cases. The acquired forms 
are characterized by a long incubation period (years) and, although being the rarest, 
are of high concern to public health. Iatrogenic CJD (iCJD, i.e. CJD due to inadvertent 
transmission during medical procedure) has occurred in a substantial number of dura 
mater graft recipients and recipients of human growth hormone derived from 
cadaveric pituitary glands (Brown et al. 2012; Ironside, Knight, and Head 2011; Ritchie 
et al. 2017). Likewise, the epidemic of variant CJD (vCJD, see Section 1.5.1.2), that 
peaked between the late 1990s’ and early 2000s’ (World Health Organisation 2003), 
has been ascribed to inadvertent animal-to-human transmission (i.e. zoonotic 
transmission) of Bovine Spongiform Encephalopathy (BSE, i.e. PrD typical of bovines) 
(Bruce et al. 1997; Ward et al. 2006) and there have been cases of vCJD secondary 
transmission by transfusion of contaminated blood products (Peden et al. 2004) or 
professional accidental exposure (ISS 2019). 
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1.5.1.1 Sporadic Creutzfeldt-Jakob disease 
Among human PrDs, sporadic CJD (sCJD) is the most common form, with an 
incidence of 1.5-2 cases per million people world-wide (Ladogana et al. 2005; Masters 
et al. 1979).  The combination of dementia and myoclonic movements, often 
associated with cerebellar features, progressing over weeks to a state of total 
disability is the classic presentation of sCJD. Variation in the clinical presentation 
largely correlates with the genotype at the polymorphic codon 129 (encoding for either 
methionine M or valine V) of the PRNP gene in combination with the molecular mass 
of the un-glycosylated PrPres. Indeed, PrPres from different sCJD subtypes shows 
distinct physicochemical properties, (i.e. electrophoretic mobility, glycoform patterns, 
infrared spectrum) and, based on the molecular mass of the un-glycosylated form, 
two types of PrPres can be distinguished in WB assay: type 1 migrating at 21 kDa and 
type 2 at 19 kDa. Based on these observations, molecular characterization of sCJD 
has defined six possible genotype/protein isotype combinations (i.e. MM1, MV1, 
MM2, MV2, VV1 and VV2 referred to as sCJD subtypes) that have been proposed to 
correlate with the major clinic-pathological phenotypes (Parchi et al. 1996; 1999). 
While MM1 and MV1 cases are phenotypically indistinguishable and are, therefore, 
merged in an individual subtype termed MM1/MV1, the MM2 cases show two distinct 
phenotypes based on cortical (MM2c) or thalamic (MM2t) histopathology. Age at 
onset, disease duration, frequency, evolution of symptoms and signs are all 
discriminating features of the different sCJD subtypes. The median age at onset of 
sCJD subtype MM1/MV1 is 68 years (range 31-86 years) slightly higher than MM2c 
(64 years, range 49-77 years)  which is similar to the median age at onset of VV2 (64 
years, 40-83 years) and MV2 (65 years, 36-83 years) (Zerr and Parchi 2018). The 
rarer subtypes VV1 and MM2t show a significant lower median age at onset of 44 
years (range 19-55 years) and 52 (26-71 years) respectively. The median disease 
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duration of sCJD is 6 months but it is strongly influenced by the molecular disease 
subtype. Namely, while the disease duration of MM1/MV1 and VV2 cases is typically 
shorter than 12 months, in all the other cases the median disease duration is between 
1 and 2 years.  
The most common sCJD phenotypical presentation is associated with subtype 
MM1/MV1 (~65% of sCJD cases). Symptoms and signs at onset in sCJD subtype 
MM1/MV1 are variable and include cognitive decline and visual signs of central origin. 
Aphasia, ataxia and myoclonus occur, in different combination, in a substantial 
number of patients with subtype MM1/MV1. The histopathologic investigation reveals 
the classic spongiform change with vacuolization located in the neuropil and in all the 
layers of the cerebral cortex and subcortical nuclei. Thalamus and basal ganglia are 
also affected, while hippocampus and brainstem are relatively spared. Upon 
immunohistochemical examination, granular deposition of PrPres is most abundant in 
the cerebral cortex and cerebellum and basal ganglia. The sCJD subtype VV2 
accounts for 15-20% of sCJD cases and is characterized by early onset of cerebellar 
symptoms and signs as well as oculomotor abnormalities and behavioural 
disturbances (Head et al. 2008) . Cognitive decline, other than memory loss and 
myoclonus, are late features. Distribution of PrPres and spongiform change depends 
on disease duration, but in contrast with subtype MM1/MV1, neocortex is generally 
spared. About 10% of sCJD cases are subtype MV2. The clinical phenotype of 
subtype MV2 shows significant similarities with VV2 but is characterized by a lower 
progression rate and slightly longer disease duration. Likewise, histopathology is 
similar between VV2 and MV2 although the latter typically present cerebellar plaques 
referred to as kuru plaques. Subtype VV1, MM1c and MM2t are the rarest. Around 
1% of sCJD cases are VV1. Early symptoms and signs include psychiatric and 
cognitive abnormalities followed later during the disease course by extrapyramidal 
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signs and ataxia. Histopathology generally shows that cortical-striatal regions are 
affected while subcortical regions are spared. The subtype MM2t is also referred to 
as sporadic Familial Insomnia (sFI) and early signs and symptoms include insomnia 
with inability to initiate and maintain sleep, although this is not invariably detected. 
The histopathology shows atrophy of the thalamus while spongiform changes may be 
absent or limited to the cerebral cortex where PrPres deposit may also be present. 
Progressive dementia and frequent aphasia and apraxia characterize sCJD subtype 
MM2c. In this subtype, the pathology shows a lesion profile similar to MM1/MV1 with 
the exception of the cerebellum, which is generally spared (Head et al. 2008; Head 
and Ironside 2012; Zerr and Parchi 2018). The sCJD classification system has been 
further refined (Parchi and Saverioni 2012) to accommodate the substantial minority 
of cases that contain both type 1 and type 2 PrPres, but this more subtle sub-
classification system has not yet been employed internationally, is difficult to apply 
retrospectively and is beyond the scope of this thesis.  
Notably, transmission studies to selected inbred strains of mice have shown that the 
above-mentioned six sCJD subtypes comprise four major human strains of prions 
(M1, M2, V1, V2) as defined by the length of incubation time, susceptibility and 
disease phenotype, as well as by the conservation of characteristic neuropathological 
lesion patterns upon serial passage in the same host (Bishop, Will, and Manson 2010; 
Moda et al. 2012). Interestingly, the V2 strain that has been proposed to account for 
both MV2 and VV2 sCJD, has been indicated as the possible contaminant to have 
caused the kuru epidemic (see Section 1.1) as well as the iCJD epidemic linked to 
growth hormone treatment in the United Kingdom (Kobayashi et al. 2014; Ritchie et 
al. 2017). Currently, the full characterization of the different sCJD subtypes require 
post mortem investigation, however, a means to discriminate sCJD intra vitam would 
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be of importance for the clinical management of patients and for caregivers as well as 
for the enrolment in future clinical trials. 
1.5.1.2 Variant Creutzfeldt-Jakob disease 
During the late 1990s, a new variant form of CJD (variant CJD, vCJD) was identified 
(Will et al. 1996). vCJD is an acquired form of PrD, which likely emerged as the result 
of human consumption of mechanically recovered meat derived from cattle affected 
by Bovine Spongiform Encephalopathy (BSE), a PrD which emerged in UK cattle in 
the late 1980s and early 1990s. (Bruce et al. 1997; Ward et al. 2006; Hill et al. 1997). 
The BSE outbreak highlighted the threat to public health posed by PrDs and resulted 
in coordinated national and international surveillance networks which allowed the 
identification of vCJD as a new form of PrD. From the clinical standpoint, variant CJD 
starts at an earlier age (mean age at onset is 29 years in UK patients) than sCJD, with 
prominent psychiatric symptoms and a mean disease duration of 14 months (Head et 
al. 2008). The vast majority of the reported vCJD cases present homozygosity with 
respect to codon 129 status, being almost exclusively MM. Transmission and 
biochemical studies have shown that the biological phenotype and PrPres isotype of 
vCJD is almost indistinguishable from the one found in BSE. These observations 
corroborated the hypothesis that vCJD emerged from the infection of susceptible 
individuals by the BSE strain of agent (Collinge et al. 1996; Bruce et al. 1997; Head 
et al. 2004). In recent years, however, one case of definite vCJD (Mok et al. 2017) 
and one case of possible vCJD  (Kaski et al. 2009) heterozygous at codon 129 (i.e. 
129MV) were described. This appears to be in line with a previous transmission study 
of vCJD in transgenic mouse lines expressing the human prion protein gene of 
129MM, MV or VV genotype, at physiological levels (i.e. single copy of the human 
PrPC gene replacing the mouse one).  The results of this study predicted a 129 
genotype-specific susceptibility to vCJD, with 129MM subjects showing the shortest 
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incubation time, followed by 129MV and 129VV individuals having the longest 
incubation time, so long that in fact they may never show signs of the (Bishop et al. 
2006).  
1.5.1.3 Human prion disease diagnosis 
Criteria for human PrD diagnosis are defined by guidelines compiled by the World 
Health Organization (WHO). According to WHO guidelines, the diagnosis of PrD firstly 
depends on the recognition of the possibility of this type of disorder upon neurological 
investigation. Electroencephalogram (EEG) registration of Periodic Sharp Wave 
Complexes (PSWC) represents an important aid for sCJD diagnosis despite having 
no definite diagnostic value, because some of the identified sCJD molecular subtypes 
and vCJD do not show alteration in EEG. Similarly, alterations in Diffusion Weighted 
Magnetic Resonance Imaging (DW-MRI) signals from specific brain structures (e.g. 
basal ganglia) and cortical ribbon are also taken into account to inform CJD diagnosis. 
Cerebrospinal Fluid (CSF) screening for the presence of 14-3-3 protein is currently 
routinely performed in suspected CJD cases. However, CSF 14-3-3 is a biomarker of 
neuronal damage and its detection in the CSF may be the result of several other 
pathologies acquiring diagnostic value only within the framework of a specific clinical 
context (Ladogana et al. 2009; Stoeck et al. 2012; Collins et al. 2006). Ultimately, 
according to the WHO diagnostic criteria, PrDs definite diagnosis is achieved only at 
post mortem (World Health Organisation 2003). Neuropathological observation 
typically reveals characteristic change in the CNS: spongiform changes, neuronal 
loss, glial activation, and PrPSc deposition, which may form amyloid plaques. PrPSc is 
the only currently available direct biomarker for PrDs and its presence in brain tissue 
is usually inferred by immunoblot detection of PrPres (see Section 1.2) following PK 
treatment in standardized conditions. The limited sensitivity of the currently available 
methods for the immuno-detection of PrPres, however, hinder their application to 
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peripheral biological tissues or fluid for diagnostic purposes. In the last decade, 
however, in vitro biochemical methodologies based on the prion replication 
mechanism have been described, which have shown the potential overcome this 
hurdle and eventually allow the intra vitam diagnosis of PrDs based the analysis of 
peripheral biological fluids. 
1.6 Cell-free conversion systems 
Cell-free conversion (CFC) systems are methodologies that emulate prion replication 
mechanism in vitro and allow amplification and, thereby, detection of otherwise 
undetectable amounts of prions. The general elements constituting a CFC system 
are: a source of PrPSc (termed seed), a source of PrPC (termed substrate), an energy 
input, tailored chemical conditions and a method to detect the conformational change 
of the substrate. CFCs were originally developed to test the protein-only hypothesis 
and investigate prion biology. Kocisko and colleagues firstly demonstrated, in an in 
vitro cell-free reaction environment, the ability of brain-derived, semi-purified PrPSc to 
convert recombinant PrP to forms that resemble naturally occurring PrPSc, by showing 
resistance to limited proteolysis (Kocisko et al. 1994). Currently, after 25 years of 
technical refinements, two methodologies represent the most common 
implementation of CFCs: the Protein Misfolding Cyclic Amplification (PMCA) and the 
Real Time Quaking Induced Conversion (RT-QuIC).  
1.6.1 Protein Misfolding Cyclic Amplification (PMCA) 
In 2001, the group led by Claudio Soto described the Protein Misfolding Cyclic 
Amplification (PMCA) reaction for the in vitro amplification of tiny amounts of PrPSc 
otherwise undetectable by immunoblotting (Saborio, Permanne, and Soto 2001). The 
archetypical PMCA reaction is a tube-based reaction that employs crude Brain 
Homogenate (BH) as a source of PrPC (substrate), which is induced by the PrPSc that 
is present in the test sample (seed) to convert into more PrPSc. The PMCA reaction 
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involves cycles of incubation at constant temperature and sonication in the ultrasound 
frequency range. The latter element constitutes the energy input and is the distinctive, 
invariant, characteristic of the PMCA method. The homogeneous distribution of the 
sound waves is achieved by partially submerging tubes in a water bath. PMCA 
reaction products are detected in a separate step by a biochemical assay. The typical 
detection system relies on the detection of PrPres by WB analysis following PK 
digestion. PMCA results are typically qualitative (i.e. Yes/No), but quantitative 
protocols have been described (Chen et al. 2010; Morales et al. 2012). 
The PMCA reaction conditions are thought to enhance the kinetics of the natural prion 
replication mechanism. Evidence has shown prion replication (involving nucleated 
aggregation and misfolding of PrP into PK resistant structures) can occur 
spontaneously in in vitro systems consisting of mouse cell lysate expressing tagged 
PrPC, mixed with semi-purified PrPSc preparations (Saborio et al. 1999) and incubated 
at constant temperature. However, in PMCA, the ultra-sound waves are thought to 
directly break PrPSc fibrils, generating new nuclei of polymerization (Saborio, 
Permanne, and Soto 2001; Moda, Pritzkow, and Soto 2013; Piening et al. 2005), 
therefore, increasing the kinetics of the reactions. At the same time, sonication in the 
ultrasound frequency range causes the repeated expansions and collapse of 
microbubbles, generating high local pressure and temperature (i.e. acoustic 
cavitation), as well as the sonolysis of water. These two latter phenomena generate 
an environment enriched in air-liquid interfaces as well as in reactive species (e.g. 
•OH and •H) that favour the misfolding of the substrate PrP and contribute to fibrils 
breaking (Haigh and Drew 2015). It has been shown that PMCA kinetics can be further 
increased by adding teflon or ceramic beads to the reaction mixture (Barria et al. 2018; 
Moudjou et al. 2016). 
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The PMCA reaction has been crucial for the investigation into critical aspects of prion 
biology. Indeed, specific PMCA protocols have allowed the production of de novo 
infectious prions from preparations of bacterially expressed recombinant PrPC and 
minimal components, corroborating the protein-only hypothesis (Deleault et al. 2007; 
Legname et al. 2004; Colby et al. 2009; Wang et al. 2010; Barria et al. 2009). Likewise, 
the observation that the PMCA reaction products, seeded with PrD samples, retain 
infectivity, PrPSc isotype and prion strain properties when inoculated in mice (Castilla 
et al. 2008; Cali et al. 2019), sustains the hypothesis that the characteristics of prion 
strain do not require a functional cell machinery to propagate and are enciphered in 
PrPSc structure. Similarly, the species barrier phenomenon is, at least in part, 
recapitulated in PMCA. Hence, PMCA has been used to investigate the potential of 
certain animal PrDs to be transmitted to humans (Barria et al. 2014; Levavasseur et 
al. 2014; Fernández-Borges, De Castro, and Castilla 2009) as well as to gain insights 
into how the transmission of sCJD and vCJD is influenced by different genotypes of 
the polymorphic codon 129 of human PRNP (Jones et al. 2008). 
Furthermore, PMCA protocols have been described that allow the detection of PrPSc 
in urine (Moda et al. 2014), blood plasma (Concha-Marambio et al. 2016; Bougard et 
al. 2016) and CSF (Barria et al. 2018) samples from vCJD cases. Nonetheless, the 
deployment of PMCA diagnostic applications on a large-scale has been limited. This 
is likely due to the fact that the substrate used for the PMCA diagnostic applications 
is the BH of transgenic mice expressing the human PrPC (Concha-Marambio et al. 
2016; Moda et al. 2014; Barria et al. 2018). Not all the laboratories involved in clinical 
diagnosis have access to animal facilities and, to maintain transgenic animal 
production is costly. The transferability of the method between laboratories is further 
hampered by the difficulties in standardizing the sonication procedure. 
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1.6.2 Real Time Quaking Induced Conversion (RT-QuIC) 
The Real Time Quaking Induced Conversion (RT-QuIC) reaction is the evolution of 
the assay developed by Kocisko and colleagues (Kocisko et al. 1994) in combination 
with certain technical features of the Amyloid Seeding Assay (ASA) developed by 
Colby and colleagues (Colby et al. 2007). RT-QuIC employs a recombinant PrP (rPrP) 
as substrate for conversion. At variance with PMCA, RT-QuIC uses intermittent 
shaking rather than sonication as energy input and does not require a separate step 
for signal detection. The RT-QuIC reaction can be followed in real time because of 
the presence of Thioflavin T (ThT) in the reaction mixture, an amyloidotropic 
fluorescent dye. ThT binds to the amyloid and amyloid-like fibril structures that are 
formed by the prion seeded misfolding of the rPrP substrate during the RT-QuIC 
reaction. The typical RT-QuIC reaction is a 96-well plate based assay, performed in 
a plate-reader that incubates samples at constant temperature, performs cycles of 
intermittent shaking and is able to detect the fluorescence emission from ThT upon 
binding to amyloid structures (Wilham et al., 2010; Atarashi, et al., 2011a; Atarashi, 
et al., 2011b).  
Since its first introduction (Wilham et al. 2010), RT-QuIC has attracted attention as 
diagnostic test for animal and human PrDs. The first studies regarding the application 
of RT-QuIC to sCJD diagnosis used the full-length (i.e. 23-230) human rPrP (FLHu-
rPrP) or the full-length (i.e. 23-231) hamster recombinant PrP (FLHa-rPrP) as the 
reaction substrate for the analysis of human CSF and brain samples (Atarashi  et al., 
2011b; McGuire et al., 2012). A subsequent study using sCJD and vCJD brain 
material showed that the use of the FLHu-rPrP, FLHa-rPrP, as well as a truncated 
(i.e. 90-231) form of the hamster rPrP (90-231Ha-rPrP), allowed the detection of 
highly diluted sCJD BH but not of vCJD BH (Peden et al. 2012). A few years later, the 
use of the FLHa-rPrP, FLHu-rPrP, and chimeric full-length sheep-hamster rPrP (SHa-
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rPrP) (Cramm et al. 2015) were internationally validated as the RT-QuIC substrates 
for the diagnostic analysis of sCJD CSF samples (McGuire et al. 2016). Around the 
same time, a second generation RT-QuIC diagnostic test for the analysis of sCJD 
CSF samples was described with improved analytical sensitivity and speed that 
employed 90-231Ha-rPrP, included a denaturant (i.e. Sodium Dodecyl Sulphate, 
SDS)  in the reaction mixture and required higher temperature and shaking frequency 
(Orrù et al. 2015a). Second generation RT-QuIC has also been validated to screen 
samples of CSF (Groveman et al. 2016).  More recently, the analysis by first 
generation RT-QuIC of  olfactory mucosa samples collected by means of nasal swab 
from CJD patient has shown the potential to further reducing the invasiveness of the 
diagnostic test (Bongianni et al. 2017; Orrú et al. 2014). Because of the high 
sensitivity, specificity and transferability between laboratories, the RT-QuIC analysis 
of CSF, has been included among the sCJD diagnostic criteria in the United Kingdom 
(https://www.cjd.ed.ac.uk/sites/default/files/criteria.pdf) and is under scrutiny to be 




1.7 Aims of the thesis 
The overarching aim of this thesis is to compare human prion amplification in PMCA 
and RT-QuIC using human sCJD and vCJD samples. The following three hypotheses 
are addressed:  
1 Comparison of RT-QuIC and PMCA kinetics of aggregation (Chapter 3) 
Hypothesis: The PMCA and RT-QuIC reaction kinetics differ when seeded with the 
same seed. 
With the aim of addressing this, the amplification performances for sCJD and vCJD 
prions of specific PMCA and RT-QuIC protocols are established by seeding the 
reactions with brain homogenate from the same sCJD and vCJD cases. Next, a 
methodology for the comparison of PMCA and RT-QuIC respective kinetics of 
aggregation is applied, which takes the specifics of the two technologies into account. 
2 Molecular Characterization of RT-QuIC products (Chapter 4)  
Hypothesis: the epitope mapping analysis of the RT-QuIC protease resistant 
products allows discrimination between sCJD subtypes. 
The products of the diagnostic RT-QuIC reaction seeded with sCJD brain or CSF 
samples, are analysed applying the same methodological principles employed for the 
molecular discrimination of PrPres types that are part of sCJD molecular subtyping.  
3 RT-QuIC seeding activity of sCJD urine samples (Chapter 5) 
Hypothesis: RT-QuIC reaction can discriminate sCJD from non-CJD urine samples. 
The RT-QuIC reaction is optimized and deployed to investigate the possibility of 




Chapter 2 General Materials and Methods 
2.1 Laboratory requirements for safe handling of TSE samples 
The Laboratory Code of Practice of the National CJD Research & Surveillance Unit 
(NCJDRSU) follows the Advisory Committee on Dangerous Pathogens (ACDP) 
indications on laboratory requirements and practices that needs to be in place to 
handle PrD tissue samples safely. According to this, all the experimental work 
presented in this thesis was carried out in a containment level 3 laboratory with certain 
derogation. Because the PrD agent is not air borne, the laboratory does not need to 
be sealable for fumigation and the laboratory extract air does not need to be HEPA 
filtered. CJD tissue sampling, homogenization to 10% weigh/volume (w/v) and 
handling of the homogenate, were performed in class 1 microbiology safety cabinet 
(MSC I) while non-CJD tissue homogenization to 10% w/v and homogenate handling 
were performed in class 2 microbiology safety cabinet (MSC II).  
2.2 Biological samples 
The CSF and tissue bank at the National CJD Research and Surveillance Unit 
(NCJDRSU), provided all the human brain, CSF and urine samples. All the human 
biological samples had ethical approval and full consent for use in research (Scotland 
A REC 05/MRE00/67, Edinburgh Brain Bank 16-ES-0084). Transgenic mouse brains, 
used as PMCA substrate (see Section 2.6), were kindly provided by Dr. Abigail Diack, 
Roslin Institute, the University of Edinburgh, UK. 
2.2.1 Human brain samples 
The brain frontal cortex of three cases of sCJD subtypes MM1, MV1, MM2 (of the 
cortical variant, MM2c), MV2, VV2 and two cases of sCJD subtype VV1 according to 
the Parchi nomenclature (Parchi et al. 1999) as well as  three cases of vCJD and one 
non-CJD control (Table 2.1), were sampled and used throughout the study. Sample 
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selection was based on presence of a full consent for research, tissue availability as 
well as a previous use of the same tissue in published studies (Bishop, Will, and 
Manson 2010; Diack et al. 2012). 
2.2.1.2 Preparation of 10% Brain Homogenates 
All human brain samples were homogenized to 10% w/v. Table 2.1 lists all the brain 
samples used. Frontal cortex of each brain was sampled twice, and each pair of 
samples were homogenized in either RT-QuIC or PMCA homogenization buffer 
(Table 2.2) generating R or P samples respectively. The samples coding allows to 
identify samples taken from the same brain and homogenized to 10% w/v in either 
PMCA or RT-QuIC homogenization buffer. For details regarding the preparation of 
the 10%BHs used to seed RT-QuIC see Section 2.5.2, while details of PMCA seed 






























































Brain tumour   1 -Ctrl BH  
Table 2.1 Human brain samples 
Samples coding allow to identify the CJD type (vCJD or the sCJD subtype), the individual brain sampled 
of a certain CJD type (BH1, 2 or 3) and the preparation protocol (P for PMCA and R for RT-QuIC seed 







 RT-QuIC PMCA 
PBS 1X 1X w/o Ca++ or Mg++ 
NaCl 150 mM 150 mM 
Triton X-100  0.5% 1% 
EDTA 1 mM none 
Complete® Protease Inhibitor 
Cocktail Roche  






Table 2.2 RT-QuIC and PMCA brain homogenization buffers composition and equipment  
All the human brain samples were homogenized with either RT-QuIC or PMCA buffer. The latter was 




2.2.2 Cerebrospinal fluid samples 
CSF samples were selected based on volume availability, testing positive in a 
previous RT-QuIC analysis, being from patients with neuropathologically-confirmed 
sCJD and with a known sCJD subtype. The selected CSF samples included three 
cases of sCJD subtypes MM1, MV2 and VV2 and two cases of MV1 and MM2c. An 
additional CSF samples was selected as negative control based on being assigned 
with diagnosis of a non-prion related neurological disease, sample volume availability 























Table 2.3 CSF samples used 
All the samples were previously tested in RT-QuIC, received definite diagnosis and had a defined 






Diagnosis Codon 129 PrP Type N of cases Coding 




  2 2 
MM2CSF1 
MM2CSF2 
 MV 1 2 
MV1CSF1 
MV1CSF2 








Negative    -Ctrl 
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2.2.3 Urine samples 
Urine samples were selected based on availability of a full consent for research and 

































-Ctrl 1 suspected sporadic, non-CJD 
-Ctrl 2 suspected sporadic, non-CJD 
-Ctrl 3 suspected sporadic, non-CJD 
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2.2.4 Definition of Seeding Activity of a biological sample 
In this thesis, the Seeding Activity (SA) is the ability or capacity of a biological sample 
to seed a cell-free conversion system i.e. to generate a True Positive (TP) signal 
according to PMCA and RT-QuIC respective detection system. The definition of TP 
signal for PMCA and RT-QuIC is given in the respective materials and methods 
Sections (see Section 3.3.10 for PMCA 2.5.4 for RT-QuIC). The definition of the SA 
of a sample is of importance for the analysis of the analytical performances of a 
specific CFC and is not included among the diagnostic criteria used to analyse the 
results of the RT-QuIC reaction. 
2.3 SDS-PAGE 
All SDS-PAGE analyses were performed using pre-cast 10% bis-tris gels (NuPAGE). 
Following preparation, samples were incubated at 100°C for 10 minutes in sample 
loading buffer (LDS4X, NuPAGE). When needed, reducing agent β-mercaptoethanol 
(βMA) was added directly to 2% in LDS4X (LSD4X/2%βMA). Electrophoretic 
separation was performed in MES-SDS buffer (NuPAGE) at 200V for a minimum 35 






Gel 10% Bis-Tris Gel NuPAGE 
Sample loading buffer LDS4X NuPAGE (NP0007) 
β-mercaptoethanol Sigma-Aldrich (60-24-2) 
Running buffer MES-SDS NuPAGE 
Towbin buffer  Glycine: Fisher Scientific (BP381-5)  
Tris Base: Corning (61-233-RR) 
Methanol: Fisher Chemicals (M/4000/PC17) 
TBST Tris Base: Corning (61-233-RR) 
NaCl: VWR Chemicals (27810 295) 
Tween 20: (SLS CHE3852) 
Blotting membrane BioRad Immun-Blot PVDF (1620177) 
Secondary Antibody Goat anti-Mouse IgG-Peroxidase Novex (A16072) 
Chemilumiscence 
system 
ECL Prime Amersham 
Photographic film  Hyperfilm ECL Amersham (28906837) 
Table 2.5 List of buffers and materials used for SDS-PAGE and WB analysis  




2.4 Western blot  
Following SDS-PAGE, gels were blotted on polyvinylidene fluoride (PVDF, BioRad 
Immun-Blot) membrane by means of wet transfer (1 hour, 0.8 A constant) using 
Towbin buffer (Towbin, Staehelin, and Gordon 1979). Following transfer, PVDF 
membranes were blocked overnight in a 5% w/v solution of non-fat dry milk in 0.1% 
Tween 20 Tris buffered saline (TBST). The following day, blocking solution was 
removed and membrane was incubated according to the conditions specific for the 
primary antibody of choice. At the end, membrane was washed three times for 10 
minutes with fresh TBST. Washed membrane was incubated for 1 hour at room 
temperature (RT) and gentle shaking with a solution of horseradish peroxidase 
conjugated secondary antibody (Goat anti-Mouse IgG, Novex) diluted 1:25000 in 
TBST. At the end, membrane was washed with two 10 minutes washes and two 5 
minutes washes with TBST before applying enhanced chemiluminescence system 
(ECL Prime Amersham). The signal was detected by digital imaging with ChemiDoc 
XRS+ (BioRad). 
2.4.1 Western Blot for the evaluation of PrPres content in sCJD and vCJD 10% 
brain homogenates 
For each sCJD and vCJD 10% BHs produced, PrPres levels were evaluated by 
western blot. A sample from each 10% BH was digested with 50 μg/mL PK (Merck 
Novagen) for one hour at 37°C, digestion was blocked by protease inactivation with 
Pefabloc SC (Roche). Samples were then diluted 1:2 four times stepwise in 
0.1%SDS/PBS and LSD4X was added to 2X. Following 10 minutes incubation at 100 
°C, samples were loaded on 10% Bis-Tris gel and run in SDS-PAGE (see Section 
2.3) along with FLHa-rPrP dilutions of known concentration. Gels were blotted as 
described in Section 2.4 and membranes probed with primary antibody 3F4 (Millipore) 
diluted 1:10000. Digital images were taken by means of ChemiDoc XRS+ (BioRad). 
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Densitometric analysis of the signal was performed using ImageLab 4.1 software 
(BioRad) as described in 2.4.2. The raw data used for the evaluation of the PrPres 
content in all the vCJD and sCJD 10%BH are reported in Appendix III. 
2.4.2 Densitometric analysis of western blot signals 
All the densitometric analyses presented in this study were performed using 
ChemiDoc XRS+ (BioRad). The software was set to take pictures every 30 seconds 
for a minimum of 20 to a maximum of 40 minutes. The image that preceded the 
appearance of signal saturation (in either the standard, when used, or in a sample of 
interest) on an individual gel, was used to perform densitometric analysis of all the 
signals on that gel. The ChemiDoc XRS+ ImageLab 4.1 software (BioRad) has a built-
in function for digital image analysis and it was used to perform all the densitometric 
analysis presented in this thesis as follows; an image area, termed volume, enclosing 
a signal of interest was defined, the same volume was used to individually encircle all 
the other signal of interest (including the standard when used) and determine the 
image signal background as well. The background signal was subtracted as a 
constant from all the other defined volumes. When a standard was used, the user 
assigned quantities to the volumes corresponding to the standard dilutions and the 
software calculated a standard curve and interpolated the unknown volumes. 
2.5 RT-QuIC 
2.5.1 RT-QuIC substrate: purification of the recombinant Hamster PrP 
An individual batch of Full-length Syrian Golden Hamster recombinant prion protein 
(FLHa-PrP, residues 23-231) was purified and used for all the RT-QuIC experiments 
presented in this thesis. Purification was performed as previously described (Wilham 
et al. 2010). Syrian Golden Hamster prnp (accession K02234) expression and 
translation from transformed E.coli Rosetta cells (Invitrogen), was obtained with 
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Overnight Express Instant TB medium (Merck Novagen). Bacteria were collected and 
inclusion bodies (IB) isolated in pellets by means of Bug Buster Master Mix (Merck 
Novagen). IB Pellets were resuspended and bound to Ni-NTA Superflow resin beads 
(Qiagen) in denaturing buffer. Resin beads were packed in column and the denatured 
protein was refolded on column by running an isocratic gradient of refolding buffer. 
Refolded protein was eluted with elution buffer and dialysed against dialysis buffer. 
Concentration was adjusted to 0.69 mg/mL by means of Amicon Ultra-15 centrifugal 
Filter Units (Merck Millipore). One mL aliquots were prepared, flash frozen and stored 
at -80°C until use. Table 2.6 lists all the buffers and materials used for the recombinant 


























Overnight Express Instant TB 
medium 
Merck Novagen (71491-4) 
 
Bug Buster Master Mix Merck Novagen (71456-4) 
Ni-NTA Super flow resin beads Qiagen (30430) 
Denaturing buffer 100 mM NaPO4, 10 mM Tris, 6M Gdn-HCl, 
pH 8 
Refolding buffer 100 mM NaPO4, 10 mM Tris, pH 8 
Elution buffer 500 mM Imidazole HCl, 100 mM NaPO4, 10 
mM Tris pH 6 
Dialysis buffer 10 mM NaPO4 pH 5.8 
Centrifugal filters Amicon Ultra-15 Merck Millipore 
(UFC901008) 
Table 2.6 List of buffers and materials used for the purification of the recombinant FLHa-rPrP. 




2.5.2 Preparation of sCJD and vCJD brain samples as RT-QuIC seeds 
As mentioned in paragraph 2.2.1, small pieces of frontal cortex were sampled from 
three cases of sCJD subtypes MM1, MV1, MM2c, VV2, two cases of sCJD subtype 
VV1 according to the Parchi nomenclature (Parchi et al. 1999) as well as three cases 
of vCJD and one non-CJD case (Table 2.1). To prepare the collected tissue samples 
as RT-QuIC seeds the samples were homogenised to 10% w/v (10%BH) in RT-QuIC 
homogenization buffer (Table 2.2) using a FastPrep-24® automated homogeniser 
(MPbio) and lysing matrix D. 
2.5.2.1 Criteria for the normalization of RT-QuIC seed input from different 
10%BH 
As mentioned in Sections 2.4.1 and 2.4.2, the levels of PrPres present in each sCJD 
and vCJD 10% BH was evaluated by WB allowing the input of seed from different 
brain samples to be normalized by PrPres content. Unless otherwise indicated, all the 
RT-QuIC reactions were seeded with 2 μL of a dilution of 10% BH in PBS accounting 
for 50 fg/μL of PrPres. 
2.5.3 RT-QuIC reaction 
RT-QuIC reaction buffer composition was as follows, PBS1X (i.e. 5 mM phosphate 
154 mM NaCl), 170 mM sodium chloride, 1 mM EDTA, 10 µM ThT. All the RT-QuIC 
reaction buffer components were purchased as concentrated stock solutions from 
Sigma-Aldrich and diluted in cell culture grade water (Corning). ThT was purchased 
as powder from the same provider and ThT solution prepared monthly as 10 mM 
solution. ThT powder was weighed and dissolved in cell culture grade water, the 
solution was then syringe filtered through a 0.22 μm filter (Merck Millipore) and kept 
at +4 °C sheltered from direct light. Recombinant FLHa-rPrP substrate was thawed 
and filtered through a 100 kDa centrifuge filter (Nanosep, Pall). Following filtering, the 
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concentration of the substrate was calculated from measuring the absorbance at 280 
nm at a 1:2 dilution in 0.1% sodium dodecyl sulphate in PBS (0.1%SDS/PBS) using 
a NanoDrop OneC (Thermo-Fisher Scientific), blanking with 0.05%SDS/PBS. The 
FLHa-rPrP was then incorporated into the reaction buffer at 0.1 μg/μL, generating a 
bulk reaction mixture. Bulk reaction mixture was aliquoted in individual reaction wells. 
The final reaction volume was 100 µL per well including seed. RT-QuIC reaction was 
performed in a sealed 96-well plate with clear bottom (Thermo-Fisher Scientific) 
incubated at 42 °C for at least 48 h in FLUOstar Optima or Omega (BMG Labtech) 
plate reader. Table 2.7 lists buffer and materials used in RT-QuIC. During the 
incubation, the plate reader performed cycles of intermittent shaking (60 seconds 
shake, 60 seconds rest) and took fluorescence bottom readings every 15 min (450 
nm excitation, 480 nm emission, gain 2000). Standard shaking frequency between 
FLUOstar Optima and Omega was different to compensate for different shaking 






H2O Corning Cell Culture grade water (25-055-CI) 
PBS 10X Sigma-Aldrich (P5493)  
NaCl 5M Sigma-Aldrich (S6546) 
EDTA 0.5 M Sigma-Aldrich (03690) 
Thioflavin T Sigma-Aldrich (T3516-5G) 
Filters Nanosep 100 kDa Omega P/N (OD100C33) 
Merck Millipore Express MILLEXGP filter unit 0.22 µm 
96-well plates Thermo-Fisher Scientific NUNC (265301) 
Plate sealing tape Thermo-Fisher Scientific Sealing Tape (235307) 
Plate readers BMG Labtech FluoSTAR Optima or Omega 
Table 2.7 List of buffer and materials used for RT-QuIC 
Catalogue numbers are reported in parenthesis following the name of the brand. 
 
 
 FluoSTAR Optima FluoSTAR Omega 
Temperature 42 °C 42 °C 
Cycle structure 
(shaking/rest) 
60 s/60 s 60 s/60 s 
Fluorescence 
measuring 
Every 15 minutes Every 15 minutes 
Double orbital shaking 
frequency 
700 900 




2.5.4 RT-QuIC data analysis: fluorescence Threshold for True Positive signal 
and criteria for positivity of a sample 
RT-QuIC datasets were processed in three stages. The first stage was the labelling 
of raw data set using the built-in function of the plate reader data analysis software 
MARS (version 3.20 R2, BMG Labtech). Labelled raw data sets were exported to 
Microsoft Excel for the second stage. Using Microsoft Excel, mean average and 
standard deviation were calculated on the first fluorescence reading on all the used 
reaction well.  The sum of the mean average of all the first fluorescence reading plus 
five standard deviation defined the fluorescence Threshold (Thr) value. As the plate 
reader reads fluorescence emission every 15 minute, it often happens that a first 
fluorescence reading equal or above Thr is followed by two consecutive readings just 
below Thr followed by a fourth reading reaching fluorescence values above the very 
first one. In this thesis, to account for the stochastic fluctuations of the RT-QuIC 
fluorescence signal, only when three consecutive fluorescence readings on an 
individual reaction well were equal or above Thr, the signal was deemed a True 
Positive (TP) signal and the time of the third reading was deemed time to threshold 
(tThr). When for one sample more than 50% of the technical replicates resulted in TP 
signals the sample was deemed positive. 
2.5.4.1 Lag-time as a measure of the seeding activity of a seed in RT-QuIC 
For positive samples (i.e. 50% of the technical replicates resulting in TP signals) the 
mean average of the tThr on all the technical replicates (including those that did not 
result in TP signals) was calculated and termed lag-time (tLag). The latter value was 
used to evaluate the seeding activity of an individual seed in RT-QuIC and to compare 




A complete description of the PMCA method and the materials used to perform it, can 
be found in chapter 3 where all the PMCA experimental results are presented. 
2.7 Statistical analysis 
All the statistical analysis presented were performed in Microsoft Office 365 Excel or 
GraphPad Prism 8.  
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Chapter 3 - Comparison of PMCA and RT-QuIC reaction kinetics 
Hypothesis: The PMCA and RT-QuIC reaction kinetics differ when seeded with the 
same seed. 
3.1 Introduction 
In order to investigate the hypothesis that PMCA and RT-QuIC reaction kinetics differ 
when seeded with the same seed, a set of aims were established to evaluate and 
compare PMCA and RT-QuIC as follow: 
1 To evaluate the in vitro seeding activity of sCJD samples by PMCA and RT-
QuIC. 
2 To evaluate the in vitro seeding activity of vCJD samples by PMCA and RT-
QuIC. 
3 To evaluate the effect of differences in sample preparations between PMCA 
and RT-QuIC (e.g. different homogenization buffers). 
4 To design and implement a specific protocol for the observation of PMCA 
reaction kinetics. 
The results Section in this Chapter firstly addresses points 1 and 2 of the above list 
showing that, when using defined PMCA and RT-QuIC standard reaction conditions, 
at least one sCJD subtype presents a robust seeding activity (see Section 2.2.4) when 
assayed in both PMCA and RT-QuIC. Therefore, this subtype can be used as a 
benchmark seed for comparing the two techniques. Secondly, to address point 3, and 
further validate the selected benchmark seed, the use of samples prepared following 
PMCA sample preparation protocol as RT-QuIC seeds is established. Lastly, the 
results of a kinetic observation of the PMCA reaction are presented and compared to 
the RT-QuIC reaction kinetics using the same sCJD seed. 
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3.2 Material and methods 
The following paragraphs contain information specific to the experiments presented 
in this Chapter. When needed and to avoid redundancies, the appropriate paragraphs 
of the General Materials and Method Chapter are referred. 
3.2.1 Biological samples 
The human brain samples listed in Table 2.1 (Section 2.2.1), homogenized to 10% 
w/v as described in Section 2.2.1.2, were used for all the experiments presented in 
this Chapter. 
3.2.1.2 Evaluation of PrPres content in PMCA and RT-QuIC seeds 
The levels of PrPres present in each sCJD and vCJD 10% BH used to seed RT-QuIC 
or PMCA were evaluated by WB with mAb 3F4 as described in Sections 2.4.1 and 
2.4.2 (see Appendix III for raw data)  
3.2.2 RT-QuIC reaction: standard conditions 
The general RT-QuIC protocol is described in Section 2.5. All the RT-QuIC 
experiments presented in this Chapter were performed in the FluoSTAR Optima plate 
reader (BMG Labtech, see Table 2.8 for the conditions used). Unless otherwise 
specified, the input of different CJD seeds was normalized to 100 fg of PrPres by 
diluting the 10%BH in PBS prior to RT-QuIC. The input of the non-CJD seed was 
normalized by diluting the sample in PBS prior to RT-QuIC to the mean average 
dilution factor used to dilute all the other CJD seeds. The volume of seed used was 




3.2.3 PMCA reaction 
3.2.3.1 Buffers and materials required for PMCA 
All buffers and materials required to perform the PMCA reaction are listed in Table 
3.1. 
3.2.3.2 PMCA substrate preparation: humanized mice 10% brain homogenate 
As mentioned in Section 2.2, transgenic mouse brains, used as PMCA substrate, 
were kindly provided by Dr Abigail Diack, Roslin Institute, University of Edinburgh, 
UK. The three lines of humanized transgenic mice expressing a single copy of the 
human PRNP gene that were used in this thesis, differed only for the PRNP codon 
129 genotypes (MM, MV or VV). The limited availability of this material affected the 
number of PMCA technical and biological replicates performed. 
Whole mouse brains stored at -80 °C were washed from frozen in Dulbecco modified 
PBS (DPBS w/o CaCl2 and MgCl2) to remove traces of blood. Working on ice under 
MSC II, washed mice brains were homogenized to 10% w/v in pre-chilled PMCA 
buffer supplemented with Complete® protease inhibitor cocktail (Roche) before use 
(see Table 3.1 for buffer composition). Homogenization was achieved by means of 
tissue grinder (Kimble Chase). The homogenate was transferred to a fresh 15 mL 
tube and centrifuged at 2000 rpm for 40 seconds in a refrigerated centrifuge (4 °C). 
After centrifugation, supernatant was retained as PMCA substrate and stored at -80 
°C in 0.6 mL aliquots until use. 
3.2.3.3 PMCA seed preparation: human sCJD and vCJD 10% brain 
homogenates 
The PMCA seeds used were human sCJD and vCJD 10% BHs (Table 2.1) in PMCA 
Buffer (Table 3.1). PMCA buffer was supplemented with Complete® protease inhibitor 
cocktail (Roche) prior to use. Tissue samples homogenization was achieved with 
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plastic mini-pestles (Eppendorf) and thorough vortexing. Homogenates were clarified 
at 2000 rpm for 40 seconds in a refrigerated centrifuge (4 °C), supernatant retained 








1% Triton-X 100 
150 mM NaCl 
1XDPBS 
Sigma-Aldrich (t9-284) 500 mL 
Powder VWR Chemicals (27810 295) 
Dulbecco modified 1XPBS w/o CaCl2 
and MgCl2 Sigma-Aldrich (D8537) 500 
mL 
Seed See Section 
3.2.3.2 
Human sCJD and vCJD 10%BH 
Substrate See Section 
3.2.3.3 






buffer added with 
protease inhibitor- 
- - - - - - - - - -  
5 mM EDTA 
1 μg/mL low 
molecular weight 
heparin 
Complete® Protease Inhibitor Cocktail 
w/o EDTA Roche 
(000000011697498001) 
 
Sigma-Aldrich (03690 100) 
 
Sigma-Aldrich (H3149) 
Reaction tubes  Thermo-Scientific (AB-0337) 0.2 mL 
thin-walled 
Tube caps  Thermo-Scientific (AB-0851) flat 
Sonicator  Qsonica Q700 
Equipped with titanium horn 
 
Table 3.1 List of buffers and materials needed to perform PMCA reaction  
Catalogue numbers are reported in parenthesis following the name of the brand. 




3.2.3.5 Standard PMCA reaction: general experimental design  
The standard PMCA reaction was a 0.2 mL PCR tube based reaction consisting of a 
dilution of PMCA seed directly into PMCA substrate (hereafter referred to as PMCA 
dilution) with a minimum of one further serial dilution into substrate. Seed and 
substrate were always matched for having the same genotype at codon 129 of PRNP 
(Ritchie et al. 2017; Barria 2014). A minimum of two technical replicates per sample 
were run in an individual PMCA reaction. The final reaction volume was always 101 
µL. Unless otherwise indicated, all the PMCA reactions were run for 48 hours divided 
in 30 minute long cycles. PMCA cycles consisted of a 20 seconds long sonication 
pulse in the ultrasound frequency range followed by incubation at constant 
temperature for 29 minutes and 40 seconds. Table 3.2 lists the equipment and the 
settings used for all the PMCA reactions presented in this Chapter. The detection 
method for the PMCA reaction products consisted of a standardized WB analysis with 
mAb 3F4 following PK digestion.  
3.2.3.5.1 Definition of “Frozen” and “Sonicated” samples and PMCA signal 
For each initial PMCA dilution and serial dilution thereof, volumes were calculated to 
obtain a final volume of 120 µL in each tube. At this stage, before starting the cycles 
of sonication/incubation of the PMCA reaction, 19 µL were sampled from each 
reaction tube obtaining the final reaction volume of 101 µL. The 19 µL of PMCA 
dilution were moved to fresh 0.5 mL tubes and stored at -80°C. These 19 µL, that did 
not enter the sonication/incubation cycles of the PMCA reaction, are termed “Frozen” 
samples as opposite to the PMCA treated samples termed “Sonicated”. The PMCA 
signal resulted from the ratio of the PrPres densitometric signal as detected by 
standardized WB analysis with mAb 3F4 following PK treatment in each Sonicated 









Sonicator Qsonica Q-700 equipped with titanium 
microplate horn 
Temperature 37 °C 
Amplitude Set at 37% generating ≈290 W per sonication 
Cycle structure 20 s/1180 s (pulse-ON/pulse-OFF) 
Reaction time 48 h 




3.2.3.5.2 Criteria for the normalization of the PMCA seed input using different 
seeds  
Different PMCA seeds were diluted at different dilution factors in the initial PMCA 
dilution. Because vCJD 10% BH consistently shows seeding activity in PMCA (Barria 
2014; Moda et al. 2014; Concha-Marambio et al. 2016; Cali et al. 2019) for all the 
PMCA reactions seeded with vCJD seeds the initial PMCA dilution factor was always 
1x10-2. Also, based on the NCJDRSU expertise in performing PMCA (Barria 2014), 
1x10-2 was as well the initial PMCA dilution factor for reactions seeded with sCJD 
subtype VV2. Therefore, the PMCA reactions seeded with vCJD or sCJD subtype 
VV2 were normalized for the input of 10% BH irrespective to the levels of PrPres.  
For all the other sCJD seeds, the initial PMCA dilution factor was selected based on 
the levels of PrPres found in each 10% BH. These PMCA seeds dilutions were 
calculated to achieve a seed-dilution at which PrPres was faintly detectable before 
amplification (i.e. in the Frozen samples) in order to clearly see the increased signal 
after PMCA.  
3.2.3.6 PMCA reaction preparation 1: substrate manipulation 
PMCA reactions were assembled working on ice, in 0.2 mL PCR tubes (Thermo 
Scientific) with a minimum of two technical replicates per sample. PMCA substrate 
aliquots were flash-thawed in distilled H2O. Working on ice, under MSC I, 12 μL from 
each 0.6 mL aliquot of PMCA substrate were discarded and substituted with 6 μL of 
EDTA 0.5 M (5 mM final concentration) and 6 μL of 100 μg/mL low molecular weight 
heparin (1 μg/mL final concentration). The mixture obtained was carefully mixed by 
inversion and pipetting. When more than one PMCA substrate aliquot of a certain 
codon 129 genotype was required to prepare a PMCA reaction, individual aliquots 
were pooled together following addition of EDTA and heparin. The required volume 
of PMCA substrate was then aliquoted in each 0.2 mL PMCA reaction tube. 
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3.2.3.7 PMCA reaction preparation 2: dilution of seed into substrate and 
generation of Frozen samples 
PMCA reaction tubes containing the required volume of PMCA substrate were moved 
under MSC II while kept on ice. The PMCA seeds were added to the respective 
substrate matching the codon 129 genotype and serial dilutions were performed. At 
the end a volume consisting of PMCA reaction mixture was disposed as waste to 
obtain the final 120 μL of PMCA reaction mixture in the last tube. At this stage, 19 μL 
were moved from each PMCA reaction to fresh 0.5 mL tubes to be stored at -80 °C 
as Frozen samples. 
3.2.3.8 PMCA reaction: standard sonication conditions 
The PMCA reaction tubes, now containing 101 μL of PMCA reaction mixture, were 
placed in a tube rack on top of the sonicator’s microplate horn. To favour an even 
distribution of soundwaves, 300 mL of water, pre-heated at 37°C, were poured in the 
sonicator’s horn. Such volume ensured that reaction tubes were submerged for half 
of their length. As the sonicator is kept inside an incubator, temperature is under 
control and set at 37 °C throughout the reaction time. PMCA reaction consisted of 
cycles of 20 seconds long sonication every 29 minutes and 40 seconds for a total of 
48 hours. Sonicator settings for standard PMCA reaction are listed in Table 3.2. 
3.2.3.9 PK digestion and WB analysis for PMCA signal detection 
At the end of the PMCA reaction time (i.e. 48 hours, unless otherwise indicated), 
PMCA tubes were moved out of the sonicator and spun for 1 minute at 2000 rpm. 
Working under MSC I, 19 μL of the PMCA reaction were moved to a fresh 0.5 mL 
tubes as Sonicated samples. The Sonicated and the respective Frozen samples were 
always processed in parallel. Each Sonicated and Frozen sample was added with 1 
µL of 1 mg/mL PK yielding a final digestion volume of 20 µL and a final concentration 
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of 50 μg/mL PK. Samples were then incubated for 1 hour at 37 °C. Digestion was 
stopped by adding 10 µL of LDS4X. Samples were immediately incubated at 100 °C 
for 10 minutes and analysed by SDS-PAGE and WB using mAb 3F4 as described in 
Sections 2.3 and 2.4. All the samples from an individual PMCA reaction were always 
blotted on an individual PVDF membrane. 
3.2.3.10 Densitometric analysis of the WB for PMCA signal detection  
The densitometric values of the PrPres signals detected for each pair of Frozen and 
Sonicated samples by WB analysis with mAb 3F4, were taken with the ChemiDoc 
XRS+ ImageLab 4.1 software (BioRad) as described in Section 2.4.2. The data were 
exported to Microsoft Excel and the ratio of the densitometric values of each 
Sonicated over the respective Frozen sample for each individual pair (i.e. S/F ratio) 
was calculated. 
3.2.3.10.1 The PMCA signal: the fold increase of PrPres after PMCA 
The S/F ratio is a measure of the increase of PrPres after PMCA. Therefore, the mean 
average of the S/F ratio calculated on each technical replicate of an individual sample 
run in an individual PMCA were used to estimate the fold increase of PrPres after 
PMCA and hence to score the seeding activity of different seeds in PMCA. 
3.2.4 PMCA for the observation of PMCA reaction kinetics  
The experiments to observe the PMCA reaction kinetics were performed as follows; 
for each sample tested, aliquots of PMCA substrate were thawed, supplemented with 
EDTA as well as low molecular weight heparin and pooled together as described in 
Section 3.2.3.6. From the PMCA substrate preparation, 118.8 µL were aliquoted into 
0.2 mL PCR reaction tubes and individual reactions were seeded with 1.2 µL of the 
PMCA seed to be assayed. At this stage, each PMCA reaction tube contained 120 µL 
of PMCA dilution with a seed concentration of 1x10-2. From each reaction tube, 19 µL 
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where moved to fresh 0.5 mL tubes and stored at -80°C as Frozen samples. The 
PMCA reaction tubes, now containing 101 µL of seeded PMCA reaction, were placed 
in a tube rack on top of the sonicator’s microplate horn. Standard PMCA reaction 
conditions, as the one described in Section 3.2.3.8, were used except for the reaction 
time that was extended to 54 hours. The PMCA reactions were sampled at time 
interval of t = 1, 6.5, 24, 30.5, 48 and 54.5 hours by moving three reaction tubes from 
the sonicator to -80°C. Selection of the time intervals was based on the NCJDRSU 
Laboratory Code of Practice that limit access to the containment level 3 laboratory to 
8 hours a day. Three technical replicates per each time point were considered. At the 
end of the 54.5 h reaction time, all the reaction tubes were thawed, spun for 1 minute 
at 2000 rpm and 19 µL moved to fresh 0.5 mL tubes as Sonicated samples. The 
Frozen and the respective Sonicated samples where then treated in parallel with PK 





For sake of clarity, the PMCA results are summarized in graphs reporting the average 
means calculated on all the technical and biological replicates tested. The complete 
PMCA raw data set can be found in Appendix II. 
3.3.1 Evaluation of sCJD and vCJD seeding activity in PMCA 
To evaluate the seeding activity of sCJD and vCJD samples in PMCA, three vCJD 
cases as well as three cases of sCJD subtypes MM1, MV1, MM2c, MV2, VV2 and 
two cases of sCJD subtype VV1 (Table 2.1) were homogenized to 10% w/v in PMCA 
homogenization buffer and assayed in three independent PMCA experiments. In each 
PMCA experiment, a set of samples including one case of each type (i.e. vCJD and 
individual sCJD subtypes) was assayed. All the seeds were assayed in PMCA using 
substrates matching for the respective codon 129 status. Figure 3.1 shows the results 
obtained, summarized by seed (i.e. vCJD and individual sCJD subtypes). 
On (mean) average, the vCJD samples assayed showed a 60-fold increase of PrPres 
signal when diluted at 1x10-2 and a 27-fold increase when diluted at 1x10-3 (Figure 3.1 
A). The sCJD subtype VV2 samples, showed a 32-fold increase of PrPres signal when 
diluted at 1x10-2 and an 11-fold increase when diluted at 1x10-3 (Figure 3.1 B). 
Overall, the sCJD subtypes MM1, MV1, MM2c, VV1 and MV2 showed a very weak 
seeding activity in PMCA (Figure 3.1C). Across these sCJD samples, the sCJD 
subtype MV2 showed the highest seeding potency with an 11-fold increase of the 







Figure 3.1 Evaluation of vCJD and sCJD subtypes seeding activity in PMCA 
Each data point represents the mean average fold increase in PrPres signal and standard deviation 
calculated across  two technical replicates run for each of the three 10%BHassayed for each sample 
type. Each 10%BH was assayed once. Fold Increase values are the ratio of the densitometric signal 
detected by WB with mAb 3F4 in the Sonicated samples over the respective Frozen samples (S/F ratio). 
The identification of the type of sample is shown on top of each graph. The mean average dilution factor 
used to seed the PMCA reaction with different seed of the same type is shown at the bottom of each 




3.3.2 Evaluation of sCJD and vCJD seeding activity in RT-QuIC 
To evaluate the seeding activity of sCJD and vCJD samples in RT-QuIC, small pieces 
of tissue were sampled from the same frozen brains used for the PMCA experiments 
presented in Section 3.3.1. The samples comprised three cases of vCJD as well as 
three cases of sCJD subtypes MM1, MV1, MM2c, MV2, VV2 and two examples of 
sCJD subtype VV1 (Table 2.1). The tissue samples were homogenized to 10% in RT-
QuIC homogenization buffer as described in Section 2.5.2 and the levels of PrPres 
content was evaluated by WB analysis as described in Section 2.4.1. The seed input 
in RT-QuIC of different sCJD and vCJD samples was normalized to 100 fg of PrPres 
(see Section 2.5.2.1). An individual batch of FLHa-rPrP was purified and used as 
substrate (see Section 2.5.1). The samples were assayed in three independent RT-
QuIC experiments with the same layout, comprising one case of each seed type (i.e. 
one vCJD sample and one sCJD sample per each of the six subtypes) a negative 
control (i.e. a non-CJD 10%BH) and a control for the spontaneous aggregation of the 
substrate without any seed (i.e. PBS). The spontaneous aggregation of the substrate 
was never observed, and no signal was observed from reactions seeded with the 
negative control. All the sCJD samples assayed consistently showed true positive 
signals (see Section 2.5.4) in at least 50% of the technical replicates tested in an 
individual RT-QuIC experiment. This result allowed for the further calculation of the 
lag time (tLag) per each sample. No signal was observed for reactions seeded with 
vCJD samples. Figure 3.2 summarizes the results obtained per each type of seed 
across the three experiments. The statistical analysis of the tLag values grouped by 
sCJD subtype was performed using the unpaired T test (two-tailed) and revealed no 












Figure 3.2 Evaluation of vCJD and sCJD subtypes seeding activity in RT-QuIC 
The graph shows the RT-QuIC results obtained from three independent experiments. In each 
experiment, one example of each sample type (i.e. vCJD and sCJD subtypes) was tested in seven 
technical replicates. Two biological replicates of sCJD subtype VV1 were analysed in RT-QuIC due to 
unavailability of tissue at time of study. Seed input from different samples was normalized to 100 fg of 
PrPres. Each data point represents the time to threshold (tThr) of individual reaction wells. Horizontal bars 
indicate the mean average (i.e. tLag) and standard deviation calculated across all the data points that 
crossed threshold. No signal was observed in vCJD, PBS (unseeded reaction wells) and -Ctrl (reaction 





3.3.3 Evaluation of sCJD and vCJD seeds in PMCA and RT-QuIC reaction: 
comparative analysis 
Grouping together the results obtained for the three vCJD seeds assayed in the 
PMCA reactions showed that the average increase of PrPres was 60-fold at dilution 
1x10-2 and 27-fold at dilution 1x10-3 (Figure 3.1 A). Notwithstanding the large standard 
deviation on the means observed for these values, which can be ascribed to the 
minimal sample size (N = 3), vCJD seeds appeared to have the highest seeding 
activity among all the seeds evaluated by PMCA. When assayed in RT-QuIC, 
however, the vCJD samples prepared from the same brain material as the one tested 
in PMCA, showed no seeding activity at all. This is in line with previous observation 
regarding the seeding activity of vCJD samples assayed in RT-QuIC using the FLHa-
rPrP (Peden et al., 2012; Orrú et al., 2015). In the same work Peden et al. also showed 
that vCJD samples in RT-QuIC showed limited or null seeding activity even when 
using other recombinant substrates such as human rPrP (FLHu-rPrP)  and truncated 
form of hamster rPrP (90-231Ha-rPrP) (Peden et al. 2012). 
The sCJD seeds showed seeding activity in both PMCA and RT-QuIC. However, 
different results were obtained with these seeds in the two CFC systems. Indeed, 
while in RT-QuIC all the sCJD samples tested presented seeding activity with no 
apparent subtype-specific difference (Figure 3.2), this was not observed for PMCA. 
The sCJD subtype VV2 showed the highest seeding activity in PMCA when compared 
to the other sCJD samples tested. On average, PMCA reactions seeded with 1x10-2 
and 1x10-3 dilutions of sCJD subtype VV2 resulted in a 32-fold and 10-fold increase 
of PrPres signal respectively (Figure 3.1 B). In RT-QuIC no statistically significant 
difference was observed when comparing the tLag values grouped by sCJD subtype.  
These data suggest that the in vitro seeding activity of a CJD sample is affected by 
the conditions used to observe it (e.g. PMCA or RT-QuIC reaction conditions). The 
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same data also indicate that the sCJD subtype VV2 showed a robust seeding activity 
in both PMCA and RT-QuIC. For this reason, sCJD subtype VV2 was selected as the 






3.3.4 Evaluation of the impact of PMCA homogenization buffer on the seeding 
activity of sCJD subtype VV2 in RT-QuIC  
To validate further the use of sCJD subtype VV2 as benchmark seed for the 
comparison of PMCA and RT-QuIC reaction kinetics, the effect of the different 
homogenization buffer on sCJD subtype VV2 seeding activity was evaluated in RT-
QuIC. In this test, the RT-QuIC reaction time was limited to 48 h to equal the PMCA 
reaction time. Brain samples used to seed PMCA and RT-QuIC were homogenized 
to 10% w/v using two protocols for the preparation of the seed material (see Table 
2.2). The same sCJD subtype VV2 brain tissue was homogenized to 10% in PMCA 
(i.e. VV2BH1P) or RT-QuIC (i.e. VV2BH1R) homogenization buffer and then used to 
seed RT-QuIC. Seed input was normalized to 100 fg of PrPres. The results obtained 
are shown in Figure 3.3. Both the seeds generated true positive (TP) signals in more 
than 50% of the technical replicates. The comparison of the tLag showed no statistical 
difference (unpaired t test) between the sample prepared in PMCA homogenization 
buffer and the one prepared in RT-QuIC homogenization buffer. Hence, sCJD 
subtype VV2 10% BH samples prepared in PMCA homogenization buffer were further 








Figure 3.3 Evaluation of the impact of PMCA homogenization buffer on the sCJD subtype VV2 
seeding activity in RT-QuIC 
Figure A: RT-QuIC results showing the mean average increase in fluorescence emission in Relative 
Fluorescence Unit (RFU) against time calculated across all the technical replicates (N = 10) run per 
sample. The dotted line represent the fluorescence threshold for positivity (Thr). Figure B: analysis of 
the results shown in A. The data points represent the tThr of the individual technical replicates that 
crossed Thr. Horizontal bars indicate tLag (i.e. mean average) and standard deviation calculated across 
all the data points that crossed Thr. PBS: unseeded reaction wells. -Ctrl: reaction wells seeded with a 




3.3.5 Comparison of standard PMCA and standard RT-QuIC reactions kinetics 
seeded with sCJD subtype VV2  
To compare PMCA and RT-QuIC reaction kinetics, brain tissue from three examples 
of sCJD subtype VV2 cases were homogenized to 10% w/v in PMCA homogenization 
buffer and used to seed both PMCA and RT-QuIC reactions. The seed input from 
different samples, was normalized by the dilution factor used to dilute the 10% BH in 
either PMCA substrate or PBS prior to RT-QuIC. The limited availability of PMCA 
substrate, allowed investigating the standard PMCA reaction kinetics in a restricted 
number of conditions regarding the dilution of seed into substrate.. Based on the 
analysis of the PMCA results when seeded with sCJD subtype VV2, the 1x10-2 dilution 
was selected. Indeed, higher dilutions appeared to seed the reaction less consistently 
(Figure 3.1 B and Figure II.2 in Appendix II). Nonetheless, in contrast with previous 
results, sample VV2BH2P did not show any seeding activity when tested in the PMCA 
kinetics assay at a 1x10-2 dilution (see Appendix II). Therefore, it was excluded from 
further analysis. 
The PMCA kinetics assay consisted of sampling the PMCA at fixed time intervals of t 
= 1, 6.5, 24, 30.5, 48 and 54.5 hours (hereafter referred to as t1, t6.5, t24, t30.5, t48, t54.5 
respectively). Figure 3.4 A, shows the mean average fold increase in PrPres signal 
calculated across each time point. No substantial increase in PrPres signal was 
detected at t1 and t6.5. At t24 a mean average 20-fold increase in PrPres signal was 
observed that further increased to a 38-fold increase at t30.6. At t48, a 47-fold increase 
was observed followed by a 43-fold increase at t54.5. The statistical analysis of the 
data (unpaired t test) showed that the differences between the fold increase values 
observed at t30.6, t48 and t54.5 was not statistically significant (Figure 3.4 A). 
When diluting the sCJD subtype VV2 seeds to 1x10-2, none of the three sCJD subtype 
VV2 samples tested showed true positive (TP) signals in RT-QuIC. By further diluting 
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the seeds to 1x10-3, over the three samples tested, TP signals were observed in less 
than 50% of the technical replicates. When higher dilutions (i.e. 1x10-4, 10-5 and 10-6) 
were used, on mean average, 98% of the technical replicates showed TP signals. The 
tLag appeared to increase with the increase of the dilution factor with 1x10-4 showing a 
tLag of 7.14 h, dilution 1x10-5 showing a tLag of 10.06 hours and dilution 1x10-6 showing 





Figure 3.4 Comparison of PMCA and RT-QuIC reaction kinetics 
Figure A; PMCA reaction kinetics when seeded with sCJD VV2 diluted 1x10-2. Each data point represents 
the mean average fold increase with standard deviation calculated across all the samples tested. Two 
technical replicates were tested per each of the three sCJD subtype VV2 10%BH. * = p value 0.03; ** = 
p value 0.003.  Figure B; RT-QuIC results showing the mean average increase in fluorescence emission 
in Relative Fluorescence Unit (RFU) against time calculated across all the technical replicates run per 
sample. The dotted line represent the fluorescence threshold for positivity (Thr) Figure C; analysis of the 
results shown in B. The data points represent the tThr of the individual technical replicates. Six technical 
replicates were tested per each of the three sCJD subtype VV2 10%BH.  Horizontal bars indicate tLag 




As mentioned in the introduction to this Chapter (see Section 3.1), the investigation 
of the hypothesis that PMCA and RT-QuIC reaction kinetics differ when seeded with 
the same seed was articulated in four aims; 
1 To evaluate the in vitro seeding activity of sCJD samples by PMCA and RT-
QuIC. 
2 To evaluate the in vitro seeding activity of vCJD samples by PMCA and RT-
QuIC. 
3 To evaluate the effect of differences in sample preparations between PMCA 
and RT-QuIC (e.g. different homogenization buffers). 
4 To design and implement a specific protocol for the observation of PMCA 
reaction kinetics. 
For the sake of clarity, the discussion of the results has been divided in subsections. 
3.4.1 Seeding activity of vCJD and sCJD in PMCA 
The results obtained regarding aim 1 can be summarised as follows: 
- When assayed in PMCA, the vCJD samples showed a more robust seeding 
activity compared to the seeding activity of sCJD samples. Among the sCJD 
samples, sCJD VV2 showed the highest seeding activity. 
The characteristic observed for the seeding activity of vCJD and sCJD samples in 
PMCA, appears to be a generalized feature of the method, irrespective to the specific 
set-up used (e.g. different substrate, seed and sonication condition) (Cali et al. 2019; 
Moda et al. 2014; Concha-Marambio et al. 2016; Barria et al. 2018). No specific 
molecular mechanism has been agreed upon that explains this phenomenon. Only 
recently, Camacho and colleagues have produced evidence showing that the 
glycosylation of the PrPC substrate, in combination with the codon 129 status, might 
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be a major factor shaping PMCA amplification abilities (Camacho et al. 2019). The 
observation regarding the seeding activity of sCJD subtype VV2 is also in line with 
previous data obtained at the NCJDRSU with the same PMCA set-up used in this 
thesis (Barria 2014) and by other researchers using a slightly different PMCA set-up 
(Camacho et al. 2019). The mechanistic explanation for this is not clear at this point 
in time. Interestingly, however, the inoculation of cases of sCJD subtype VV2 in the 
same transgenic mouse line used in this thesis to produce the PMCA substrate (i.e. 
expressing PRNP with codon 129 genotypes VV, see Section 3.3.3.2), produced 
clinical signs with the shorter incubation time when compared to the other five sCJD 
subtypes inoculated in the same host (i.e. PRNP with codon 129 genotypes VV) as 
well as in mice expressing  PRNP with codon 129 genotypes MM or MV (Bishop, Will, 
and Manson 2010). In in vivo models, the length of the incubation time, is often related 
to the rate of PrPSc formation and accumulation following inoculation. Within this 
theoretical framework, a short incubation time in vivo suggests a fast rate of PrPSc 
formation. The robust seeding activity of sCJD subtype VV2 observed in PMCA, might 
then be determined by the same factors influencing the rapid rate of PrPSc formation 
observed in vivo when sCJD VV2 was inoculated into the transgenic mouse line used 
to produce the PMCA substrate.  
3.4.2 Seeding activity of vCJD and sCJD in RT-QuIC 
The results obtained regarding aim 2 can be summarised as follows: 
- When assayed in RT-QuIC using the FLHa-rPrP substrate, the vCJD samples 
did not show any seeding activity while the sCJD samples showed a robust 
seeding activity irrespective of the sCJD subtype. 
The characteristic observed for the seeding activity of vCJD and sCJD samples in RT-
QuIC seems to be influenced by the specific set-up used (e.g. substrate, seed, 
shaking and incubation condition). For instance, in term of substrate selection, the 
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use of rPrP from bank vole (i.e. FLBV-rPrP), allowed the detection of the in vitro 
seeding activity of vCJD samples as well as sCJD samples (Orrù et al. 2015a; 2017). 
The natural propensity of the bank vole PrP sequence to misfold and aggregate 
(Kobayashi et al. 2019) may perhaps provide some insights regarding the ability of 
the derived rPrP to act as universal substrate in RT-QuIC (Orrù et al. 2015b). Adding 
to this, the misfolding propensity of the Bank vole prion protein appear to match with 
the in vivo transmission studies performed for this model (Watts et al. 2014; Pirisinu 
et al. 2013). Similarly, using second generation RT-QuIC (Orrù et al. 2015a), Foutz 
and colleagues (Foutz et al. 2017), reported the discrimination of sCJD subtypes on 
the basis of the shape of the RT-QuIC reaction kinetics seeded with human sCJD 
CSF samples.  
Nonetheless, based on the experimental results obtained for this thesis, the selectivity 
for sCJD over vCJD appears to characterize the RT-QuIC set-up used. Notably, such 
selectivity appears to be in line with previous observations obtained with RT-QuIC 
reactions using FLHa-rPrP, 90-231Ha-rPrP and a SHa-rPrP as reaction substrates 
seeded with sCJD and vCJD samples  (Peden et al. 2012; Orrù et al. 2015b; Peden 
et al. 2014). This evidence suggests that the use of the hamster PrP might be a major 
determinant of the selectivity for sCJD over vCJD. It might be premature, however, to 
propose a molecular description of this phenomenon as it has only been reported in 
RT-QuIC. Indeed, even though the hamster in vivo model has been extensively used 
to characterize scrapie, there is a scarcity of data regarding inoculation of hamster 
with sporadic or variant CJD. In one study (Thomzig et al. 2006), hamster inoculated 
with mouse-adapted BSE showed accumulation of PrPres in brain and muscle. This 
evidence suggest that the hamster PrPC could be susceptible to conversion in vivo to 
the PrPSc form by BSE prion. Such evidence, when combined with existing knowledge 
regarding the link between BSE and vCJD (see Section 1.5.1.2), allow to speculate 
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that the hamster recombinant PrP could be converted in vitro in a specific RT-QuIC 
set-up which has yet to be defined. 
3.4.3 Comparative study of PMCA and RT-QuIC reaction kinetics 
Based on the results obtained, sCJD subtype VV2 was selected as benchmark seed 
for the comparison of PMCA and RT-QuIC reaction kinetics as it showed seeding 
potency in both the methods. The selection of the sCJD subtype VV2 as benchmark 
seed was further validated by addressing the issue regarding the different sample 
preparation in PMCA and RT-QuIC (i.e. aim 3, see Section 3.4). Indeed, as described 
in the general materials and method Chapter (see Section 2.2.1.2 and Table 2.2), 
PMCA and RT-QuIC seeds were prepared in slightly different homogenization buffer 
(i.e. different detergent concentration and ionic strength) and tissue homogenization 
was achieved by two different methods (i.e. automated for RT-QuIC and manual for 
PMCA). To assess if these differences affected the seeding activity of sCJD subtype 
VV2, a direct comparison of the two preparative method was performed. Specifically, 
a sCJD subtype VV2 seed prepared for PMCA was assayed in RT-QuIC along with 
the same seed prepared for RT-QuIC. The results showed that no significant 
difference could be detected between the seeding activities of the two preparations 
with the experimental conditions used. This result allowed the use of samples 
prepared for PMCA as seeds for the RT-QuIC reaction. 
To study the kinetics of the PMCA reaction in comparison with the RT-QuIC one (i.e. 
aim 4, see Section 3.4), a specific PMCA protocol was designed and implemented 
involving a selection of the dilution of sCJD subtype VV2 into substrate (i.e. 1x10-2) 
and the sampling of the PMCA reaction at selected time intervals. The seed dilution 
selected for the PMCA kinetics, however, showed no seeding activity in RT-QuIC. 
The RT-QuIC reaction appear to be inhibited when seeded with a 1x10-2 dilutions of 
seed and showed poor seeding activity at dilution 1x10-3. A similar inhibition effect 
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has been previously reported with this, as well as other RT-QuIC set-ups, so that it 
appears to be a general feature of the method (Wilham et al. 2010; Orrù et al. 2012). 
The inhibition of the RT-QuIC reaction with concentrated seeds marks a difference 
with PMCA for which such an effect has never been reported.  
The results obtained for the PMCA reaction kinetics showed no increase of PrPres 
signal (i.e. PMCA signal) at t1 and t6.5 while a significant increase was detected at t24 
further increasing at t30.5. There were not statistically significant differences in the 
values obtained after t30.5, suggesting the conversion reaction had plateaued. Notably, 
the trend designed by the data, resembled a sigmoidal shape characterized by an 
initial lag-phase (t1 and t6.5) followed by a steep increase (t24 and t30.5) reaching a 
plateau (t48 and t54.5) which is typical of protein misfolding and aggregation (Cohen et 
al. 2013). The sigmoidal profile is in fact much more apparent in the shape of the RT-
QuIC reaction which is a kinetic observation of the seeded misfolding and aggregation 
of the recombinant substrate. 
The qualitative comparison of the two reactions kinetics, shows that the RT-QuIC 
reaction, even at the lowest seed dilution tested (i.e. 1x10-6), appear to be much 
quicker than PMCA. Specifically, the RT-QuIC kinetics when seeded with seed 
dilutions in between 1x10-4 to 10-6 reached the plateau phase well within the 24 hours. 
According to the data, PMCA kinetics was within the raising phase at t24 and t30.5. 
Beyond this point, the RT-QuIC reaction reached a plateau phase where no significant 
variation in signal could be discriminated.   
PMCA signal is given by the WB detection of PrPres. The latter derives from the limited 
proteolysis of samples known to contain PrPSc. As mentioned in the introduction, PrPSc 
is thought to have a fibrillary amyloid-like structure (see Section 1.2). Hence, the 
PMCA kinetics follows the formation PrPSc fibrillary conformation(s) that when, 
subjected to limited proteolysis, yield PrPres. RT-QuIC signal consists of readings of 
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fluorescence at a specific wavelength emitted by the dye Thioflavin T (ThT) when it 
binds to amyloid and amyloid-like structures (Wilham et al. 2010). The structure(s) 
assumed by the rPrP during the RT-QuIC, under conditions similar to the one used 
here, resemble naturally occurring PrPSc as they assume resistance to limited 
proteolysis, however their limited proteolysis yield a product with different structural 
and biochemical characteristics to PrPres(Atarashi, Satoh, et al., 2011b; McGuire et 
al., 2012; Piconi et al., 2019). It is conceivable that the difference in timing between 
PMCA and RT-QuIC reaction kinetics when seeded with the same seed, might results 
from a combinatorial effects of the differences in the misfolding landscapes of the two 
different substrates (i.e. a highly purified rPrP lacking post-translational modification 
as opposite to the much more complex composition of a 10% BH containing fully 
formed PrPC) and the sensitivity and linear range of the different detection systems. 
The data presented in this Chapter suggest that, despite the methodological 
differences argued for the two cell-free conversion systems, the use of a specific 
subtype of sCJD (i.e. sCJD VV2) might allow an approximation to perform additional 
comparative studies for these two methods in the future.   
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Chapter 4: Molecular characterization of RT-QuIC products 
Hypothesis: the epitope mapping analysis of the RT-QuIC protease resistant 
products allows discrimination between sCJD subtypes. 
4.1 Introduction 
As described in the introduction, sCJD subtypes are defined by the PrPres type found 
in brain samples in combination with the genetic status of PRNP at codon 129. The 
sCJD subtypes loosely correlate with different disease presentation and clinical 
course and are currently most often discriminated at post mortem. The rate of post 
mortem examination, however, is falling in the United Kingdom (The National CJD 
Research & Surveillance Unit 2017). This may potentially impact on the ability of the 
laboratories specialized in CJD surveillance to confirm the different types of prion 
disease, particularly in cases where the clinical presentation is atypical or where prion 
disease may not have been considered. A possible aid to sCJD classification may 
come from RT-QuIC. Theoretically, a sCJD diagnostic RT-QuIC test informative of 
the sCJD subtype would provide valuable information regarding the disease course. 
Such information would be useful to caregivers, to the clinicians managing affected 
individual and possibly to stratify patients recruited in future clinical trials (Piconi et al. 
2019).  A strategy to approach this search of information is to study the structure of 
the RT-QuIC reaction products. Recently, evidence has been produced showing that 
the molecular characteristics of different prion seeds exert detectable, seed-
discriminating effects on the RT-QuIC reaction outcomes. Such effects are apparent 
either in term sCJD subtype-specific variation of the second generation RT-QuIC 
reaction kinetics (Foutz et al. 2017) or in the structural characteristics (as detected by 
IFTR spectroscopy and conformational stability assay) of the products of the RT-QuIC 
reaction seeded with mouse adapted prion strains (Sano et al. 2014; Sano, Atarashi, 
and Nishida 2015). 
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The hypothesis formulated in this Chapter stems from these observations. To 
investigate it, the same methodological principles used for the typing of the naturally 
occurring PrPres were applied to the analysis of the RT-QuIC reaction products. 
Namely, the products of RT-QuIC reaction, using FLHa-rPrP and seeded with sCJD 
BH and CSF samples, were assayed for their resistance to limited proteolysis and the 
length of the resistant fragments was investigated via epitope mapping using a panel 
of six commercially available antibodies, including those usually employed for sCJD 
molecular typing of post mortem brain tissue as part of the molecular diagnosis. This 
approach, even with low resolution when compared with biophysical methods, is 
informative of the structural conformation assumed by the recombinant substrate 
(Silva et al. 2015).  
The methodology was initially optimized by analysing the products of RT-QuIC 
reactions seeded with a set of 10%BH including the six most common sCJD subtypes. 
Preliminary observations were then validated on three biological replicates per sCJD 
subtype (except for sCJD subtype VV1, because no tissue was available at the time 
of study). Next, the method for the analysis of the RT-QuIC reaction products was 
applied to the products of the RT-QuIC reaction seeded with sCJD CSF samples (i.e. 
diagnostic RT-QuIC reaction).  
4.2 Materials and Methods 
4.2.1 Biological samples CJD and non-CJD brain and CSF samples 
For information regarding the human sCJD and non-CJD brain and CSF samples 
used, refer to the paragraphs 2.2.1 and 2.2.2 (Tables 2.2 and 2.3). Brain samples 
were homogenized to 10% w/v in RT-QuIC homogenization buffer (Table 2.2) as 
described in 2.5.2. 
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4.2.3 RT-QuIC reaction seeded with 10%BH 
All the RT-QuIC reaction seeded with 10%BH presented in this Chapter were 
performed as described in 2.5. 
4.2.4 Diagnostic RT-QuIC reaction seeded with CSF samples 
When RT-QuIC (see Section 2.5) was seeded with 15 µL of undiluted CSF it was 
configured as in the diagnostic RT-QuIC protocol currently employed internationally 
for the diagnosis of sCJD (McGuire et al. 2016). 
4.2.4.1 Criteria for the analysis of the diagnostic RT-QuIC reaction results  
According to the RT-QuIC diagnostic criteria, a CSF sample is deemed a true positive 
if at least two technical replicates of that sample in the same RT-QuIC run, cross the 
fluorescence threshold of 10000 RFU by 90 h using the BMG LabTech Optima 
FLUOstar plate reader (McGuire et al. 2016). 
4.2.5 Standard RT-QuIC untreated controls: the “Mix” samples 
For all the RT-QuIC experiments presented in this Chapter, a volume of PBS 
accounting for the absence of seed (15 µL of CSF or 2 µL of a 10% BH dilution) was 
added to the excess of reaction mixture prepared each time. These mock reaction 
mixtures were then stored in 1.5 mL polypropylene tubes (APEX® NoStick™ Alpha 
Laboratories) at -20°C. These samples, termed “Mix”, were used as RT-QuIC 
untreated controls in subsequent immunochemical analyses of the RT-QuIC reaction 
products. 
4.2.6 RT-QuIC reaction products collection 
At the end of each RT-QuIC run, the sealed plate was removed from the plate reader 
and allowed to equilibrate at room temperature in MSC I. Condensation was spun 
down with 1 min centrifugation at 4500 rpm in a SIGMA 3-16K (rotor sigma 11240 
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337/F). Working in the MSC I, sealing tape was removed and the contents of the wells 
collected by carefully scraping the wells internal surfaces with a disposable pipette 
tip. Samples were stored in 1.5 mL polypropylene tubes (APEX® NoStick™ Alpha 
Laboratories) at -20°C until use. 
4.2.7 SDS-PAGE and WB analysis to assess the efficiency of the collection of 
RT-QuIC reaction products 
To estimate the amount of RT-QuIC reaction products collected, densitometry 
following WB with mAb 3F4 was performed on the collected RT-QuIC reaction 
products. SDS-PAGE analysis was performed as described paragraph 2.3 with a 
specific modification in the method used for sample preparation: namely, 6 μL of neat 
RT-QuIC reaction products were diluted 1:1 in 0.1%SDS and LDS Sample Buffer 
(NuPAGE) was added to 2X. Samples were incubated for 10 minutes at 100 °C and 
then loaded onto the gel along with FLHa-rPrP dilutions of known concentrations. 
Electrophoretic run conditions were 200 V constant for 40 minutes. At the end, gels 
were blotted as described in Section 2.4 using mAb 3F4 as primary antibody. 
Densitometric analysis of the WB signals were performed as described in 2.4.2.  
4.2.7.1 Coomassie staining 
Coomassie Brilliant Blue R250 (Thermo-Fisher Scientific) was purchased as powder 
and solution prepared fresh monthly (Table 4.1). Following SDS-PAGE, gels were 
incubated overnight in 50 mL Coomassie solution at room temperature with gentle 
shaking. The following day, stained gels were removed from Coomassie solution, 
rinsed with distilled water and incubated for at least 1 h in destaining solution at room 
temperature with gentle shaking. Images of the de-stained gels were taken with 





















Table 4.1 Coomassie staining and destaining solutions composition  
 Composition 
Staining solution 0.1% w/v Coomassie R250 
10% v/v Glacial acetic acid 
40% v/v Methanol 
in distilled water 
Destaining solution 10% v/v Glacial acetic acid 
40% v/v Methanol 
in distilled water 
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4.2.8 PK digestion of RT-QuIC reaction products 
For each digestion experiment, PK (Merck Millipore) was diluted fresh on the day from 
a glycerol stock to working stock in cell culture grade water. PK working stock 
concentrations were calculated to digest RT-QuIC reaction products with different 
amounts of PK using the same final digestion volume of 80 μL. The final digestion 
volume included 76 μL of sample and 4 μL of the appropriate PK working stock dilution 
to obtain the desired final concentration of protease. Digestions were carried out in 
0.5 mL propylene tubes at 37 °C for 1 hour and stopped by placing the tubes on ice. 
PK activity was irreversibly inhibited by adding Pefabloc® SC (Sigma-Aldrich) to 1.25 
mM. 
4.2.9 Methanol precipitation of PK digested RT-QuIC reaction products 
Products of PK digestion were methanol precipitated with 10 volumes of - 20°C 99.9% 
pure methanol (Fisher Chemicals). Samples, with added methanol, were thoroughly 
vortexed and incubated overnight at -20 °C. The following day, the samples were 
centrifuged for 35 minutes at 18200 x g (Eppendorf 5417R, rotor 06/09 HL128), the 
supernatant was discarded, and residual methanol evaporated by incubating the open 
tubes at 100°C in MSC II. Pellets were resuspended in 42 μL of 0.1%SDS/PBS, half 
of the volume was moved to a fresh tube and added to an equivalent volume of either 
LDS4X/2%βMA (reduced samples) or LDS4X with no βMA (non-reduced samples). 
4.2.10 SDS-PAGE of PK treated and PK untreated RT-QuIC reaction products  
The PK treated samples were prepared as described in 4.2.6 and .7, while for PK 
untreated samples 15 μL were diluted 1:1 in 0.1%SDS/PBS (final volume 30 μL), split 
in two fresh 0.5 mL tubes as 15 μL aliquots and combined with LDS4X/2%βMA or 
LDS4X to 2X, thus generating reduced and  non-reduced samples, respectively. 
Samples were incubated at 100 °C for 10 minutes before loading on a 10% Bis-Tris 
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gel. The volume of sample loaded in each lane of an individual gel was always 10 μL, 
irrespective of being PK treated or untreated. The SDS-PAGE analysis was 
performed as described in 2.3. 
4.2.11 WB analysis of the PK treated and PK untreated RT-QuIC reaction 
products 
The general WB method used is described in paragraph 2.4. Additionally, at the end 
of the SDS-PAGE described in 4.2.8, the gels were blotted on the same PVDF 
membrane. Following transfer (see Section 2.4 for conditions), the PVDF membrane 
was split into Sections corresponding to individual gels, each Section being incubated 
with a different primary antibody. Performing the WB analysis with different primary 
antibodies on samples that had been transferred together increased the reliability of 
this comparison by reducing the variation in transfer efficiency.  
4.2.12 Primary antibodies used and selection criteria 
The criteria used to select the monoclonal antibodies for this project were the 
following: 
- Being routinely employed for PrPres typing. 
- Monoclonality and known epitope sequence. 
- Binding to an epitope encompassed in the PrPC folded domain that is known 
to be involved in the re-folding that generates PrPSc. 
- Ideally, but not exclusively, raised against hamster PrP antigens. Indeed, the 
main component of RT-QuIC reaction products is the RT-QuIC substrate 
FLHa-rPrP. This component is present in large excess compared to the seed. 
However, as PrP sequences are highly conserved among mammals (ref to 




Table 4.2 lists the antibodies used while the diagram in Figure 4.1 shows the position 
of the epitope of each antibody on the PrP primary structure. 
 
 

















89-93 1:10000 RT Yes 
3F4 Millipore 106-112 1:10000 RT Yes 




155-161 1:1000 RT Yes 
















Figure 4.1 Diagram of Syrian golden hamster PrPC primary sequence truncated at position 89 
indicating relevant features as well as positions of the mAbs epitopes 
Coloured boxes indicate positions of the epitopes recognised by each mAbs. Each box is colour coded 
to an individual mAb. For each mAb, epitope position in indicated. Dark grey boxes indicate positions of 
α-helices. The α-helix 2 and α-helix 3 are linked by the disulphide bridge (S-S) between cysteine residues 






4.3.1 Preliminary validation of the selected monoclonal antibodies used 
Each monoclonal antibody was individually tested to confirm its ability to bind the RT-
QuIC untreated FLHa-rPrP in a WB assay. The concentration of a sample of the 
FLHa-rPrP batch used as substrate in all the RT-QuIC experiment was measured and 
serial dilution of known concentration prepared in reducing conditions. The generated 
standard stock was used to initially test the reactivity of all the selected mAb (Figure 
4.2). The results of this preliminary analysis showed that 12B2, 3F4 and SAF70 
consistently detected 2 to 10 ng of RT-QuIC untreated FLHa-rPrP (Figure 4.2 A, B 
and D) while 8H4 and 94B4 weakly detected 50 ng and 6H4 did not bind to the 
recombinant PrP at all under the conditions used (Figure 4.2 C, E and F). 
The results obtained using 6H4, 8H4 and 94B4 highlighted the need to modify the 
protocol to increase the detection limit of these mAbs to levels comparable to those 
presented by 12B2, 3F4 and SAF70. The results showed that the binding of 6H4, 8H4 
and 94B4 was negatively affected by the presence of the reducing agent β-
mercaptoethanol (Figure 4.3). Therefore, this component was excluded from the 
preparation of samples to be probed with these mAbs. With the appropriate reducing 






Figure 4.2 Validation of the monoclonal antibodies used and effect of the reducing agent β-
mercaptoethanol 
A) Testing mAbs ability to bind RT-QuIC untreated FLHa-rPrP in WB. FLHa-rPrP dilutions of known 
concentration were prepared in presence of 1% reducing agent β-mercaptoethanol. The same FLHa-
rPrP was used to test all the mAbs. B) RT-QuIC untreated FLHa-rPrP dilutions were prepared with (+) 
or without (-) reducing agent β-mercaptoethanol (βMA), run on the same gel and probed with 6H4, 8H4 






4.3.2 Assessing the efficiency of RT-QuIC reaction products collection method 
Preserving the integrity of the misfolded conformation assumed by the recombinant 
substrate during RT-QuIC was a prerequisite to investigate the hypothesis that the 
conformation(s) of the RT-QuIC reaction products were dependent on seed subtype. 
To achieve this, the RT-QuIC reaction products were collected from the plate wells 
without using any detergent or denaturant.  
A preliminary analysis of the samples collected in this way from individual reaction 
wells showed, however, that the amounts of recombinant protein collected was not 
reproducible (Figure 4.3 A and B). This was considered an issue because samples 
that contained very low amounts of FLHa-rPrP might introduce bias into the analysis. 
Low recovery of FLHa-rPrP following a limited treatment with PK, might produce PK 
resistant fragments, below the limit of detection of the selected antibodies.  
To address this problem, the replicated wells were pooled together upon collection 
from the plate, which reduced the differences in FLHa-rPrP content between samples, 
minimising bias (Figure 4.4 A). Washing the wells with a mild denaturant solution (i.e. 
0.1%SDS/PBS) and analysing the generated samples by WB with mAb 3F4 showed 
that the missing substrate was, at least in part, adherent to the well walls (Figure 4.4 
B). This material was not analysed further as it was collected in a buffer containing a 








Figure 4.3 Efficiency and reproducibility of RT-QuIC end-product collection from individual 
reaction wells 
[A] Coomassie staining of RT-QuIC products collected from individual reaction wells. Samples are coded 
according to well position on the 96-well plate. [B] Densitometric analysis of gels in A. As no standard 
was used, Volumes Intensity values measured by the Image Lab software (BioRad) are reported. Mean 







Figure 4.4 WB analysis of pooled RT-QuIC technical replicates and wells washes  
The pictures show one representative blot of two technical replicates. Histograms report the mean 
average and standard deviation of the densitometric signal measured on the two technical replicates of 
the blot. [A] WB of the RT-QuIC reaction products pooled by technical replicates and densitometric 
analysis of the signals [B] WB of the well washes pooled by technical replicates and densitometric 
analysis of the signals. WBs gels layout is mirrored in the arrangement of the histogram columns; 
samples are named after the seed content. 1) MM1BH1R; 2) MM2cBH2R; 3) MV1BH2R; 4) MV2BH2R 
5) VV1BH1R 6) VV2BH2R 7) -Ctrl 8) PBS; 9) MM1BH3R; 10) MM2cBH3R; 11) MV1BH3R; 12) 
MV2BH3R 13) VV2BH3R. kDa: kiloDalton; MM: Molecular weight Marker. Immunodetection was with 
mAb 3F4 1:10000  
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4.3.3 Detection the PK untreated RT-QuIC reaction products with the selected 
monoclonal antibody 
The optimization of the method for collecting the RT-QuIC reaction products (4.3.2), 
showed that this material was readily detected by mAb 3F4 as an individual band an 
apparent molecular mass corresponding to the RT-QuIC untreated FLHa-rPrP. The 
same observation was repeated for each of the mAbs in the panel. The samples 
analysed were from an individual RT-QuIC experiment in which the reaction was 
seeded with a dilution of a 10% BH for each sCJD subtype and included a negative 
control and an unseeded control for the spontaneous aggregation of the substrate. 
Samples were prepared as describe in 4.2.9. The results showed that all the 
antibodies in the panel detected the PK untreated RT-QuIC reaction products. Indeed, 
irrespective of the antibody used and whether RT-QuIC product was seeded, 
unseeded or from an RT-QuIC untreated control (i.e. mix), PK untreated RT-QuIC 
reaction products were invariably detected as an individual band running at the same 
molecular weight as the RT-QuIC untreated FLHa-rPrP (Figure 4.5). Taken together 
these results indicated as well that the sample preparation was effective in disrupting 










Figure 4.5 Epitope map of PK untreated RT-QuIC reaction products 
The six gels were transferred on an individual PVDF membrane which was subsequently split in Sections. 
Individual membrane Sections were incubated with different primary antibodies. The mAbs and dilutions 
used are indicated on top of each WB picture. RT-QuIC reaction products are identified by the seed 
content 1) MM1BH1R; 2) MM2cBH1R; 3) MV1BH1R; 4) MV2BH1R; 5) VV1BH1R; 6) VV2BH1R; 7) -Ctrl; 
8) PBS; 9) Mix; 10) 2 ng FLHa-rPrP; 11) 10 ng FLHa-rPrP. kDa: kiloDalton; MM: molecular weight marker.  
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4.3.4 Limited proteolysis of RT-QuIC reaction products with low PK 
concentration and epitope mapping of the resistant fragments 
Treating the same RT-QuIC reaction products previously analysed in 4.3.3 with PK at 
10 μg/mL, dramatically reduced and, in some instance, abolished the signal from all 
the mAbs except SAF70, which in contrast detected additional bands (Figure 4.6). 
Signals at an apparent molecular mass corresponding to the PK untreated FLHa-rPrP 
were clearly detected by mAbs SAF70, 3F4, 8H4 and 94B4 (Figure 4.6 B, C, D and 
F) with the highest intensity detected in the RT-QuIC untreated mixture sample.  
Such a high intensity was very likely due to the higher concentration of FLHa-rPrP 
present in the RT-QuIC untreated mixture sample. Indeed, this sample was not 
affected by the loss of material due to the prolonged contact with wells surfaces of the 
RT-QuIC plate in contrast to the other RT-QuIC reaction products. Furthermore, the 
signals at an apparent molecular mass corresponding to the PK untreated FLHa-rPrP 
suggested that, with the conditions adopted, the amount of PK used produced a 
limited digestion of the FLHa-rPrP present in solution.   
Regarding the additional bands detected by SAF70, a new band was detected at ~ 
22 kDa as well as a prominent band at ~10 kDa (Figure 4.6 B). This latter band was 
not detected by SAF70 in the RT-QuIC reactions seeded with the negative control or 
PBS suggesting that it was specific to the sCJD seeded RT-QuIC reaction products. 
Indeed, even though the RT-QuIC untreated mixture sample showed a signal 
between ~5 to 15 kDa, it was smeared. Such a smeared signal was most likely the 









Figure 4.6 Epitope map RT-QuIC reaction products treated with 10 µg/mL PK 
The six gels were transferred on an individual PVDF membrane subsequentially split in patches. 
Individual membranes were incubated with different primary antibodies. The mAb and dilution used are 
indicated on top of each WB picture. RT-QuIC reaction products are identified by the seed content 1) 
MM1BH1R; 2) MM2cBH1R; 3) MV1BH1R; 4) MV2BH1R; 5) VV1BH1R; 6) VV2BH1R; 7) -Ctrl; 8) PBS; 
9) Mix; 10) 10 ng FLHa-rPrP; 11) 50 ng FLHa-rPrP; 12) 2 ng FLHa-rPrP. kDa) kiloDalton; MM: molecular 
weight marker.  
 
100 
4.3.5 Limited proteolysis of RT-QuIC reaction products with higher 
concentrations of PK and the epitope mapping of resistant fragments  
To further investigate whether the ~10 kDa band, detected by SAF70, was indeed 
due to the FLHa-rPrP acquiring PK resistance during the sCJD seeded RT-QuIC 
reaction, or resulted from the incomplete digestion of the FLHa-rPrP, the same 
samples analysed in 4.3.4 were treated with increased concentration of PK. The 
limited proteolytic treatment was carried out with 30 or 50 μg/mL PK. The latter 
enzyme concentration corresponds to the one routinely used when screening 10% 
BH samples for the presence of PrPres. This amount of PK is considered enough to 
achieve the digestion of most if not all the PK sensitive PrP isoforms in solution 
allowing for the unhindered immunodetection of PrPres. 
When the RT-QuIC reaction products treated with 30 or 50 μg/mL PK were probed 
with SAF70, no signal was detected from the negative control seeded sample, the 
unseeded sample and the RT-QuIC untreated mixture sample. An intense signal at 
~10 kDa was instead clearly detected in all the sCJD seeded RT-QuIC products 
samples irrespective of the sCJD subtype (Figure 4.7 B and C). 
All the other antibodies in the panel failed to detect, in the same samples, signals of 
intensities comparable to the one detected from SAF70. However, occasionally, very 
faint bands were detected by mAbs other than SAF70 at a molecular weight 
corresponding to the intact FLHa-rPrP and more rarely at 22 kDa (see S1 Figure in 
Appendix I).  Notably, however, the signal detected by SAF70 at ~22 kDa appeared 
to reduce progressively with the increase of PK (Figure 4.7 A, B and C) suggesting 
that it resulted from the incomplete digestion of the FLHa-rPrP rather than 









Figure 4.7 RT-QuIC products treated with 10, 30 or 50 µg/mL PK and probed with mAb SAF70 
1:1000 
The figure summarises the results obtained with mAb SAF70 for the RT-QuIC end-products treated with 
PK at A 10, B 30 and C 50 µg/mL PK. RT-QuIC reaction products obtained from the same RT-QuIC 
experiment and used in A, B, C are identified by the seed content 1) MM1BH1R; 2) MM2cBH1R; 3) 
MV1BH1R; 4) MV2BH1R; 5) VV1BH1R; 6) VV2BH1R; 7) -Ctrl; 8) PBS; 9) Mix; kDa: kiloDalton; MM: 
molecular weight marker. The results obtained when probing these samples with the other mAbs in the 





4.3.6 Preliminary conclusions and validation of the observed banding profile of 
the PK treated RT-QuIC reaction products 
The preliminary optimization of the method used for the epitope mapping analysis 
following limited PK treatment of the RT-QuIC products seeded with sCJD 10%BH, 
indicated that: 
- RT-QuIC products seeded with a sCJD seed were characterised by resistance 
to limited proteolytic treatment up to 50 μg/mL PK.  
- The core of the protease resistant conformation assumed by the FLHa-rPrP 
during the RT-QuIC reaction encompasses the SAF70 epitope, and no sCJD 
subtype-specific difference, in term of electrophoretic mobility or abundance, 
were apparent. 
To validate these observations, biological replicated samples of RT-QuIC reaction 
products were produced and analysed. Two additional examples of sCJD 10%BH 
subtypes MM1/MV1, MM2c, MV2, VV2 and one example of sCJD subtype VV1 were 
assayed in RT-QuIC (Figure 4.8 A). The RT-QuIC products were collected by pooling 
together replicated wells and the samples obtained were treated with 50 μg/mL PK in 
parallel with the same samples used during the optimization phase (BH1R sample 
set). Following PK treatment, the samples were analysed by WB with mAb SAF70.  
The results of this analysis are shown in Figure 4.8 B. In line with the previous results, 
a band at MW ~10 kDa was clearly detected by SAF70 in all the samples analysed, 
irrespective to the sCJD subtype. A weaker signal was also detected with an apparent 
molecular mass of ~22 kDa in most of the analysed samples, but with no apparent 
correlation to the sCJD subtype. It should be noted that a similar, if not identical, ~22 
kDa signal was detected in the RT-QuIC products seeded with MM2cBH1R analysed 





Figure 4.8 Comparative analysis of RT-QuIC reaction products seeded with 10%BH dilutions 
[A] Three examples of sCJD 10%BH subtype MM1/MV1, MM2c, MV2, VV2 and 2 examples of subtype 
VV1 were run in standard RT-QuIC. The BH1 sample set was run in eight technical replicates per sample 
whereas BH2 and BH3 sample set were run in six technical replicates per sample. For each sample, the 
time to threshold of individual technical replicates that crossed Thr is shown. Bars indicates the mean 
average and standard deviation calculated on each group of technical replicates that crossed Thr. [B] 
The products of the RT-QuIC reactions presented in A were collected, treated with 50 μg/mL PK and 
analysed in WB with mAb SAF70 1:1000. In both A and B samples are arranged in the same order and 




4.3.7 Analysis of the products of RT-QuIC reaction seeded with CSF samples 
CSF samples from all the different sCJD subtypes except sCJD VV1 were assayed 
in three independent RT-QuIC analyses. The results of the RT-QuIC analysis showed, 
as expected based on the sample selection criteria, that all the different CSF samples 
assayed satisfied the diagnostic criteria for positivity (McGuire et al. 2016). Even 
though spontaneous aggregation of the substrate was observed in two out of 20 
unseeded reaction wells, none of the negative controls showed aggregation-
associated fluorescence increase. The tThr of individual diagnostic RT-QuIC reaction 
wells are reported in Figure 4.9 A. 
Following the same experimental design as with 10%BH, the diagnostic RT-QuIC 
reaction products were collected by pooling replicated wells together. The samples 
were subsequently treated with 50 μg/mL PK and analysed by WB with mAb SAF70. 
No signals were apparent from the PK treated RT-QuIC products seeded with the 
negative control (i.e. non-CJD CSF sample) or from the unseeded RT-QuIC reactions. 
All the sCJD seeded RT-QuIC reaction products instead, showed a similar if not 
identical banding pattern characterised by two prominent signals at around 10 and 22 
kDa irrespective of the sCJD subtype of the CSF sample used to seed the reaction 







Figure 4.9 Comparative analysis of diagnostic RT-QuIC reaction products 
[A] Time to threshold of individual reaction wells that crossed Thr is reported with mean average and 
standard deviation. CSF samples from all the different sCJD subtypes except sCJD VV1 were assayed 
in seven technical replicates in three independent RT-QuIC analysis using the same non-CJD CFS and 
negative control. -Ctrl) negative control; PBS) unseeded control for the spontaneous aggregation of the 
substrate. [B] The products of the RT-QuIC reactions presented in A were collected, treated with 50 
μg/mL PK and analysed in WB with mAb SAF70 1:1000 along with FLHa-rPrP dilutions of known 
concentration. rec) 10 ng of FLHa-rPrP. In both A and B samples are arranged in the same order and 










The generation of PK resistant material from the prion seeded conversion of a 
recombinant substrate was first reported by Kocisko and co-workers (Kocisko et al. 
1994) and has been subsequently exploited in different CFCs as a detectable sign of 
the prion seeded conversion of PrPC, or of recombinant PrP substrates along with, or 
instead of, alterations in ThT fluorescence (Atarashi et al. 2008). More recently, Sano 
and co-workers used two different rodent adapted prion strains and mouse rPrP as 
reaction substrates and showed that RT-QuIC reaction products retain some of the 
strain specific biochemical properties such as the conformational stability and β-sheet 
structure (Sano et al. 2014; Sano, Atarashi, and Nishida 2015). However, the same 
authors were unable to discriminate strain-specific structural differences by epitope 
mapping of PK digested RT-QuIC reaction products using the mAb ICSM35 (epitope 
93-102) and the polyclonal PrP antiserum R20 (epitopes 218-231). These results 
were in line with previous findings obtained with sCJD seeds, showing that the 
conformation acquired by the seeded RT-QuIC reaction products confers PK-
resistance to a C-terminal domain encompassing the R20 epitopes (Wilham et al. 
2010). In addition, the banding profile detected with R20 by Sano and colleagues was 
specific to prion seeded RT-QuIC reaction products but independent of the rodent 
prion strain used as seed. Similar results have been obtained with R20 by McGuire 
and colleagues (McGuire et al. 2012) on a limited number of PK-treated RT-QuIC 
reaction products generated with human 10%BH and CSF sCJD seeds and 
employing FLHa-rPrP as a reaction substrate. In both these studies only very mild PK 
treatments using 10 and 6 µg/mL PK respectively were performed, prior to western 
blotting. The present study expands on these observations by systematically 
investigating the extent of PrP primary structure that is encompassed by the RT-QuIC 
PK resistant reaction products generated by sCJD seeds, by employing six 
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commercially available monoclonal antibodies and harsher proteolytic conditions that 
are discriminatory for subtyping sCJD brain tissue itself. 
The initial assessment of the sensitivity of the selected mAbs towards the RT-QuIC 
substrate FLHa-rPrP in WB, showed that the binding of mAbs 6H4, 8H4 and 94B4 to 
their respective epitopes was negatively affected when the reducing agent β-
mercaptoethanol was added to the sample loading buffer (Figure 4.2). The reducing 
agent was added to reduce and thereby break the one disulphide bond in PrP 
(cysteine 179- cysteine 214, Figure 4.10 A), favouring the linearisation of the protein 
structure by LDS and preventing the rPrP intermolecular dimerisation while in the 
denatured state. The fact that reducing conditions suppressed the binding of mAbs 
6H4, 8H4 and 94B4 suggests that the correct presentation or availability of the 
epitopes recognised by these mAbs may depend on the local secondary structure of 
the protein, i.e. specific amino acid residues at the epitopes must be spatially arranged 
in a specific conformation. The disruption of the 6H4 epitope by reduction and 
alkylation has been reported previously (Yuan et al. 2005). The data presented here, 
however, show that reducing conditions and the consequent disruption of the 
disulphide bond distal to the 6H4 epitope, is enough to reduce or suppress 6H4 
binding. No previous report was found instead regarding of the negative effect of 
sample reduction on 8H4 and 94B4 binding. However, in the latter case, the supplier 
(Central Veterinary Institute at Wageningen University, Netherlands, EU) states in the 
product information sheet that the 94B4 epitope is “assumed to be conformation 
dependent”, hence its binding may be susceptible to the conformational modifications 
determined by the reducing agent. 
The cysteine at position 179 that forms one half of the disulphide bridge, is part of 
8H4 epitope (Zanusso et al. 1998; Li et al. 2000) and the latter is followed on the C-
terminal side by the 94B4 epitope (Yull et al. 2006). Hence, the 8H4 and 94B4 
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epitopes are contiguous and map on one arm of the hairpin loop that may remain 
intact when the protein is denatured, and the disulphide bond is oxidised. It is 
therefore conceivable that the disruption of the hairpin loop by reduction of the 
disulphide bridge may lead to a conformational rearrangement that in turn negatively 
affects the 8H4 and 94B4 epitopes.  
In the absence of reducing conditions and when no PK treatment was used, all the 
antibodies used detected both the FLHa-rPrP substrate prior to RT-QuIC and the 
FLHa-rPrP recovered from the plate following RT-QuIC (Figure 4.2 and 4.5).  The 
treatment of the RT-QuIC reaction products with 10 µg/mL PK, was enough to negate 
the signal detected by all the selected antibodies apart from SAF70 (Figure 4.6). The 
fragment detected by SAF70 was specific to sCJD seeded RT-QuIC reactions and 
has an apparent molecular weight of around 10 kDa (Figure 4.10 B). The latter 
estimate was made on the basis of the migration distance on western blot and is 
therefore only approximate. Nevertheless, the SAF70-detected band was observed 
irrespective of the sCJD subtype or whether brain or CSF was used to seed the 
reaction (Figures 4.8 B and 4.9 B). Moreover, the fragment detected with SAF70 was 
unaffected by the harsher PK treatment used (i.e. 50 µg/mL PK,). Taken together 
these observations indicate the fragment detected by SAF70 represents the PK 
resistant conformational core generated during sCJD seeded RT-QuIC reactions. 
The negative results obtained after PK digestion using mAbs that recognise more N-
terminal epitopes, namely 12B2 and 3F4, indicate that these parts of FLHa-rPrP are 
digested by even the mildest PK treatment used in this study. This observation is in 
line with previously published evidence regarding RT-QuIC reaction products 
generated with human and non-human prion seeds, indicating that in the 
conformation generated during RT-QuIC the C-terminal region of the recombinant 
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substrate acquires PK resistance (Wilham et al. 2010; McGuire et al. 2012; Sano et 
al. 2014; Sano, Atarashi, and Nishida 2015) 
The apparent molecular weight of the fragment detected by SAF70 cannot be 
reconciled easily with the lack of detection by 6H4 and 8H4 because the region of 
hamster PrP between 6H4 and 8H4 epitopes has a much smaller molecular mass 
(~2.7 kDa) than the apparent molecular mass of 10 kDa (Figure 4.10 B). Taking into 
consideration the observed susceptibility of the 6H4 epitope to distal conformational 
changes (Figure 4.10 B), it is possible that the structural integrity of this epitope was 
affected by the proteolytic digestion of either or both the N-terminal and C-terminal 
domains, rather than by a direct effect of the PK. It is also possible that the observed 
loss of 8H4 and 94B4 signals might arise from a secondary conformational effect 
resulting from PK exerting its activity on distal domains so that the sequence 
encompassing these epitopes may contribute to the observed molecular weight of 
~10 kDa. In particular, PK activity may determine an outcome similar to the one 
determined by the reducing agent (i.e. the disruption of the hairpin loop between α2 
and α3), by exerting its activity on the hinge between the arms of the hairpin loop 
(Figure 4.10 A). The digestion of the hinge may lead to a topological change in the 
local sequence that negatively affects 8H4 and 94B4 binding without destroying the 
peptide sequence encompassing their epitopes. 
The results presented here show that the RT-QuIC reaction products, generated by 
seeding the reaction with either sCJD brain samples or sCJD CSF samples, are 
partially resistant to PK digestion. The PK digestion of the sCJD seeded RT-QuIC 
reaction products yields a fragment that is detected by mAb SAF70 at a molecular 
weight of ~10 kDa. The epitope mapping analysis showed that the same banding 
profile is observed irrespective of the sCJD subtype used to seed the RT-QuIC 
reaction and irrespective to seed being a sCJD brain or CSF samples. These results 
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suggest that all the sCJD seeds have induced the same conformational change in the 
FLHa-rPrP irrespective of PrPres type or sCJD subtype of the seed.  
This conclusion allows to speculate that the sCJD brain and CSF samples share a 
similar if not identical component capable of inducing the generation of similar RT-
QuIC reaction products. Alternatively, the selection of the conformation(s) assumed 
by the substrate might be entirely due to the purified FLHa-rPrP conformational 
uniformity and RT-QuIC reaction conditions. The highly purified recombinant FLHa-
rPrP might offer a limited conformational landscape (too much order) that does not 
allow the selection of specific conformational pathways within the time frame of the 
RT-QuIC reaction kinetics. More complex and sensitive molecular methodologies or 
a different set of mAb, directed towards the domains surrounding of SAF70 epitope, 
may be able to better characterise the products of the protein misfolding events taking 
place during RT-QuIC. These data may eventually permit this technique to 








Figure 4.10 Diagram of Syrian golden hamster PrPC primary sequence truncated at position 89 
and putative sequence of the PK resistant core of RT-QuIC products 
[A] Coloured boxes indicate positions of the epitopes bind by the mAbs used. Each box is colour coded 
to an individual mAb. For each mAb epitope position in indicated. Dark grey boxes indicate positions of 
α-helices. The α-helix 3 and α-helix 2 are juxtaposed by the disulphide bridge (S-S) between cysteine 
residues 179 and 214 forming a hairpin loop. H: hinge. [B] Minimal extent of the fragment detected by 




Chapter 5: RT-QuIC seeding activity in sCJD urine samples 
Hypothesis RT-QuIC reaction can discriminate sCJD from non-CJD urine samples 
5.1 Introduction 
The investigations regarding the shedding of prions in urine of humans and of other 
animals, has been traditionally hampered by the lack of methodologies capable of 
reliably detecting direct or indirect markers of prions in this easily accessible biological 
fluid. Shaked and colleagues, firstly reported the immunodetection by WB analysis of 
protease resistant prion protein isoforms in urine samples from patient affected by 
genetic prion disease (Shaked et al. 2001). Following studies on larger sample sets 
showed, however, that the detection of protease-resistant material with the method 
used by Shaked and collaborators resulted from antibodies cross-reacting with 
aggregated fragments of light-chain immunoglobulins (Head et al. 2005; Kariv-Inbal 
et al. 2006; Dabaghian et al. 2008). Prion infectivity has been observed by bioassay, 
in urine from prion infected mice affected by concomitant nephritis (Seeger 2005) and, 
at very low titre, in urine of hamsters experimentally inoculated with hamster adapted 
scrapie strain (Kariv-Inbal et al. 2006; Gregori et al. 2008). However, early 
transmission studies in primates (Brown et al. 1994) and a more recent bioassay 
investigation (Notari et al. 2012) did not detected infectivity in urine samples of 
humans affected by sCJD. 
The introduction of CFC systems for the ultrasensitive detection of prions represented 
a major technology change in this field. Moda and colleagues (Moda et al. 2014) 
demonstrated, for the first time, that urine samples from vCJD patients seed the 
PMCA reaction when using humanized transgenic mouse 10%BH as substrate and 
multiple round of PMCA. In contrast, sCJD and gCJD urine samples gave a negative 
result when tested using the same conditions. The PMCA method used by Moda and 
collaborators, in spite of technical differences when compared to the PMCA method 
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discussed in Chapter 3, is similarly poorly seeded by sCJD brain samples (Cali et al. 
2019). Hence, the authors could not reject the hypothesis that the lack of seeding 
activity observed in sCJD and gCJD urine samples was in fact due to the analytical 
limitations of the method used. 
The hypothesis addressed in this Chapter is that RT-QuIC can detect prion-related 
seeding activity if it is present in sCJD urine. RT-QuIC analysis of urine samples has 
been successfully applied to follow disease progression in rodents experimentally 
inoculated with a mouse-adapted scrapie strain (Shi et al. 2015). In addition, a CWD 
diagnostic RT-QuIC test, based on urine analysis (as well as saliva and faeces), has 
been optimized and adopted in laboratories involved in the surveillance of CWD 
(John, Schatzl, and Gilch 2013; Henderson et al. 2015a; 2015b; Denkers et al. 2016). 
Additionally, the sCJD diagnostic RT-QuIC test based on CSF analysis demonstrate 
the ability of RT-QuIC to detect prion related seeding activity in a biological fluid 
characterized by very low titre of infectivity and by inference low amount of prions 
(Brown et al. 1994). 
The existing literature suggests that, in order to detect prion related seeding activity 
by either PMCA or RT-QuIC in urine samples, they need to be concentrated by 
centrifugation (Moda et al. 2014) or fractionated by chemical and physical treatments 
(Denkers et al. 2016; Shi et al. 2015). In this Chapter, two methods to prepare urine 
samples, before RT-QuIC, are derived from the relevant literature and tested on an 
artificial sCJD urine reference standard as well as on actual sCJD urine samples. The 
first method, based on the work by Moda and collaborators (Moda et al. 2014), entails 
pelleting urine samples by ultracentrifugation and using the resuspended pellets to 
seed RT-QuIC. The second method, termed Iron Oxide Magnetic Extraction (IOME), 
is derived from Denkers et al., 2016 and exploits the known affinity of prions for metal 
surfaces (Zobeley et al. 1999). 
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5.2 Materials and methods 
5.2.1 Biological samples 
For information regarding the human sCJD and non-CJD urine samples used, refer 
to paragraphs 2.2.3 and Table 2.4. The sCJD subtype MM1 10%BH, used as positive 
control to the RT-QuIC reaction as well as to generate the model of sCJD urine, was 
MM1BH1R (see 2.2.3 and Table 2.1). 
5.2.1.2 Artificial sCJD urine reference standard 
In a preliminary analysis, it was observed that the RT-QuIC reaction was inhibited 
when neat urine spiked with sCJD 10%BH was used as seed. Such inhibition was 
abolished when spiked urine were dialysed against 1XPBS. Therefore, to model the 
shedding of prions in urine, sCJD 10%BH MM1BH1R was serially diluted in 1XPBS. 
The dilutions (hereafter referred to as spikes) were used as surrogates for actual 
sCJD urine samples. Following preparation, spikes were frozen at -80 °C to simulate 
storage conditions of the actual urine samples.  
5.2.2 RT-QuIC reaction 
All the RT-QuIC reactions presented in this Chapter were performed as described in 
Section 2.5 on a FLUOstar Omega (BMG Labtech) plate reader (Table 2.8). Seed 
volume was always 2 µL irrespective to sample preparation. 
5.2.2.1 Preparation of urine samples: pelleting by ultracentrifugation 
Urine samples were cleared by centrifugation for 5 min at 2000 rpm generating 
supernatant S1 and pellet P1. A 3 mL volume of S1 was loaded in Slide-A-Lyzer™ 
Dialysis Cassette (7 kDa membrane cut-off, Thermo-Fisher) and dialysed at RT 
against 100 volumes 1XPBS (pH 7.4). The dialysate was changed after 1 h and 
dialysis continued overnight. The sample was then retrieved from the dialysis cassette 
generating DS1 samples. The DS1 samples were further ultra-centrifuged at 100,000 
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g for 1h at 4 °C generating supernatant S2 and pellets P2. Table 5.1 lists the 
ultracentrifuge equipment and conditions used. Supernatants S2 were discarded 
whereas pellets P2 were resuspended in 20 μL of PBS and 2 µL of this used to seed 
individual RT-QuIC reaction wells. The sCJD urine reference standard (5.2.1.2) was 
treated as if it were a DS1 sample, namely, 3 mL were pelleted as described above 







Ultracentrifuge Optima Max, Beckman Coulter 
Rotor MLS-50, swinging bucket, Beckman Coulter 
Tubes Open-top thick-wall, Beckman Coulter 
Conditions 40,000 rpm 1 h at 4 °C 
 
Table 5.1 Ultracentrifuge equipment and settings 
 
 
Figure 5.1 Pelleting by ultracentrifugation (PBU) 
Diagram depicting the method used to pellet urine samples  
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5.2.2.2 Preparation of urine samples: Iron Oxide Magnetic Extraction, IOME 
Superparamagnetic iron oxide beads (~ 9 μm in diameter) were purchased from Bang 
Laboratories (Indiana, US) as a suspension at 49 ng/μL. Using a magnetic separation 
rack, 2 μL of beads per sample were washed twice in 500 µL of 1XPBS. Washed 
beads were incubated overnight at RT on a head-to-head rotator with 800 μL of urine 
supernatant S1 (generated as described in 5.2.2.1) or an equal volume of sCJD urine 
reference standard (5.2.1.2). The following day, using a magnetic separation rack, 
samples were removed, beads were resuspended in 20 µL of 1XPBS and 2 µL used 




Figure 5.2 Iron oxide magnetic extraction (IOME) 





5.3.1 RT-QuIC analysis of urine following PBU 
Preliminary evaluation of ultracentrifugation as a means of concentrating seeding 
activity from sCJD urine samples was conducted using the sCJD 10%BH sample 
MM1BH1R serially diluted from 1x10-3 to 1x10-12 in 1XPBS. Following 
ultracentrifugation, the pellets were resuspended in PBS and assayed in RT-QuIC 
along with a standard positive control for the RT-QuIC reaction, (i.e. 2 µL of dilution 
of MM1BH1R containing 100 fg of PrPres) and a negative control constituted by 
reactions seeded with 1XPBS (Figure 5.3 A).  
One out of 5 technical replicates of the negative control showed a TP signal at around 
80 hours. According to the criteria for positivity applied in this thesis (see Section 
2.5.4) the control was considered negative. Overall the results showed that, by means 
of pelleting by ultracentrifugation, it was possible to reliably retrieve seeding activity 
in spikes diluted from 1x10-3 to 1x10-6 with lag times increasing with the increasing 
dilution of the reference standard. True positive signals were also observed in 
individual wells seeded with spikes diluted at 1x10-7, 10-8, 10-10, 10-11. As these signals 
occurred in less than 50% of the replicated wells, the samples were considered 
negative. 
The pelleting procedure was then applied to actual urine samples. In this instance one 
non-CJD urine samples (i.e. -Ctrl 1) and three sCJD urine samples (i.e. U1, U2, U3) 
were assayed along with a standard positive control and unseeded samples (Figure 
5.3 B). TP signals were observed in two out of six PBS seeded wells while no signals 
were observed in the negative control and the positive control presented with a tLag of 
8.49±0.24 hours. Of the three sCJD urine samples assayed, only one out of six 
reaction wells seeded with sample U1 showed TP signal while exactly 50% of the 
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wells seeded with sample U2 or U3 did. Therefore, none of the sCJD urine samples 





Figure 5.3 RT-QuIC analysis of urine following PBU 
Data points indicate the time to threshold for each technical replicate (N = 6) per individual sample. Bars 
indicate the mean average (i.e. tLag) and standard deviation calculated for those samples showing signals 
in more than 50% of the technical replicates. In [A] PBS spiked with sCJD 10%BH MM1BHR from 10-3 
to 10-12, pelleted by ultracentrifugation and used to seed RT-QuIC. In [B] three sCJD urine samples (i.e. 
U1, U2, U3) and one non-CJD urine sample (i.e. –Ctrl 1). PBS) unseeded sample; MM1BH1R) positive 
control.   
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5.3.2 RT-QuIC analysis of urine following IOME 
The ability of the paramagnetic iron oxide beads to bind and extract prion seeding 
activity from samples during Iron Oxide Magnetic Extraction (IOME) was tested on 
PBS spiked with sCJD 10%BH MM1BH1R at dilutions ranging from 10 -1 to10-12. 
Beads incubated overnight with PBS only (i.e. IOME PBS) were also assayed in the 
experiment. The IOME PBS sample had a double function, to act as negative control 
to the spikes and, when compared with the unseeded sample (i.e. PBS), to assess 
whether the presence of the beads effected the spontaneous aggregation of the 
reaction substrate. A standard positive control (i.e. 2 µL of dilution of MM1BH1R 
containing 100 fg of PrPres) was tested as well (Figure 5.4 A). 
No TP signals were observed in the unseeded sample, whereas two wells out of five 
seeded with PBS IOME did show TP signals. The PBS IOME sample was deemed 
negative because TP signals were detected in less than 50% of the technical 
replicates, however, this result suggested that the iron oxide beads did promote the 
misfolding and aggregation of the unseeded reaction substrate (Figure 5.4 A).  
The results obtained from reaction wells seeded with beads that were incubated with 
sCJD urine reference standard, showed that by means of IOME it was possible to 
extract RT-QuIC detectable seeding activity from dilutions of 10% BH ranging from 
1x10-1 to 1x10-6. Seeding activity was also detected in reactions seeded with beads 
incubated 1x10-8 to 1x10-11 dilution of sCJD 10% BH (Figure 5.4 A). Next, three non-
CJD urine samples and seven sCJD urine samples were treated with IOME and the 
beads used to seed the RT-QuIC reaction (Figure 5.4 B). Adopting the criteria for 
positivity used in this thesis (see Section 2.5.4) the RT-QuIC analysis of these 
samples resulted in one false positive out of three negative controls and four false 
negatives out of seven sCJD urine samples. Based on these results, the RT-QuIC 
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analysis of IOME treated urine samples show a sensitivity of 42.9% and a specificity 









Figure 5.4 RT-QuIC analysis of IOME treated samples 
Data points indicate the time to threshold for each technical replicate per individual sample that crossed 
the Thr. Bars indicate the mean average (i.e. tLag) and standard deviation calculated on the replicated 
wells that crossed the Thr for each samples showing TP signals in more than 50% of the technical 
replicates (N = 5). In [A] PBS samples spiked with sCJD 10%BH MM1BHR from 10-1 to 10-12 were 
incubated with iron oxide beads and the beads used to seed RT-QuIC. PBS IOME) RT-QuIC reaction 
seeded with beads incubated with PBS only. In [B] three non-CJD urine samples (-Ctrl 1, 2 and 3) and 7 
sCJD urine sample (U1-U7) were treated iron oxide beads and the beads used to seed RT-QuIC. PBS) 




The results presented in this Chapter represent a first attempt at investigating the use 
of RT-QuIC to discriminate sCJD from non-CJD urine samples. With respect to the 
RT-QuIC conditions employed when seeding the reaction with sCJD brain material or 
CSF, no modifications were introduced in the RT-QuIC reaction in terms of 
temperature, shaking frequency, reaction buffer and reaction substrate, while two 
different methods were investigated to prepare the samples to be tested. These 
methods were deployed with the aim of concentrating (i.e. pelleting) or extracting (i.e. 
IOME) seeding activity from the samples prior to RT-QuIC analysis.  
Both methods were first tested on reference standard sCJD urine generated by 
diluting a sCJD 10%BH in PBS and the two methods produced different results. When 
using the pelleting method, seeding activity was detected at dilutions down to 1x10-6 
with individual reaction wells presenting with TP signals beyond this dilution point 
(Figure 5.3 A). In contrast, the iron oxide beads used for IOME, were able to extract 
seeding activity from samples diluted down to 1x10-11 (Figure 5.4 A). There was an 
anomaly at the dilution 10-7 where, TP signals in two out of five technical replicates 
were observed. In addition, judging from the results observed for the PBS IOME 
sample, the presence of the beads appeared to increase the spontaneous 
aggregation propensity of the substrate. 
The low sensitivity achieved with the pelleting method was also observed upon 
analysis of actual urine samples. Of the three sCJD urine samples tested, none tested 
positive using the criteria adopted in this thesis. It is to be noted, however, that for two 
out three of the sCJD urine samples tested (i.e. U2 and U3) exactly 50% of the 
technical replicates showed TP signals (Figure 5.3 B). This result suggests that less 
stringent criteria for positivity might be better suited to analyse the results of this test.    
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Similarly, the characteristics of the IOME method deduced from the analysis of the 
sCJD urine reference standard (i.e. high sensitivity and positive effect on the 
spontaneous aggregation of the substrate) were confirmed upon analysis of actual 
urine samples. When using the IOME method, seeding activity was detected in three 
out seven of the sCJD urine samples, but also in one out three of the negative controls 
(Figure 5.4 B). Interestingly, of the three sCJD urine samples that tested positive, two 
(i.e. U2 and U3) showed TP signals in 50% of the technical replicates when the 
pelleting method was used. Considering the small sample size, the IOME method 
coupled with RT-QuIC appears to be 42.9% sensitive and 66.6% specific in 
discriminating sCJD urine samples from non-CJD ones. 
Taken together, these data suggest that coupling RT-QuIC with specific sample 
preparation strategies and a post hoc study for the selection of specific criteria for 
positivity, may have the potential to achieve the discrimination of sCJD from non-CJD 
urine samples. In particular, the IOME method used in this study appears to be more 
promising than the one based on urine samples pelleting. Further experiments are 
needed to confirm these results and to explore the possibility of achieving levels of 
sensitivity and specificity that will allow the development of a sCJD diagnostic test 
based on urine analysis by RT-QuIC.  
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Chapter 6: General Discussion 
6.1 Overview of the results obtained 
The overarching aim of this thesis was to describe and compare the in vitro human 
prion amplification by PMCA and RT-QuIC and to extend the diagnostic applicability 
of the latter, which is currently employed for the diagnosis of sCJD. The results 
presented in Chapter 3 show that vCJD samples, when assayed in PMCA, showed a 
more robust seeding activity compared to the seeding activity of sCJD samples and 
that, among the sCJD samples, sCJD subtype VV2 showed the highest seeding 
activity. Conversely, when assayed in RT-QuIC using the FLHa-rPrP substrate, the 
vCJD samples did not show any seeding activity while the sCJD samples showed a 
robust seeding activity irrespective of the sCJD subtype. Moreover, for the first time, 
PMCA and RT-QuIC reaction kinetics were compared using a specifically designed 
protocol and the same benchmark seed (i.e. sCJD VV2). In Chapter 4, a biochemical 
analysis of the RT-QuIC reaction products obtained by seeding the reaction with sCJD 
brain and CSF samples was presented. The results show that in term of the extent, 
abundance and electrophoretic mobility of the PK resistant core of the RT-QuIC 
products no sCJD subtype- or seed-specific differences were apparent (Piconi et al. 
2019). Moreover, the RT-QuIC reaction was optimised and deployed to investigate 
the possibility of developing a clinical diagnostic test for sCJD based on the analysis 
of patient urine samples. The results of the latter study are presented in Chapter 5 
and show that coupling RT-QuIC with specifically designed sample preparation and 
data analysis methods may allow the discrimination of sCJD urine samples. 
6.2 Molecular characterization of human prion amplification in cell-free systems 
As discussed in Chapter 3, PMCA preference for vCJD over sCJD appears to be a 
general feature of the method, irrespective of the set-up used (Moda et al., 2014; 
Concha-Marambio et al., 2016; Barria et al., 2018; Cali et al., 2019). Likewise, the 
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efficient amplification of sCJD VV2 by PMCA, has been reported by other authors 
(Barria 2014; Jones et al. 2008) and appears to be in line with the results obtained 
from transmission studies using the transgenic mouse line which was the source of 
the PMCA substrate for the experiments presented in this  thesis (Bishop, Will, and 
Manson 2010). The results obtained with RT-QuIC instead appear to be specific to 
the RT-QuIC set-up based on the substrate FLHa-rPrP (used in this thesis) as well as 
of the RT-QuIC set-ups based on substrates 90-231Ha-rPrP, FLHu-rPrP and hamster 
sheep chimeric rPrP  (Peden et al. 2012; Orrù et al. 2015b; Levavasseur et al. 2017). 
The evidence indicating that the symmetry between PMCA and RT-QuIC in amplifying 
variant or sporadic CJD prions can be overcome by modification of the PMCA (i.e. 
deglycosylaton) and RT-QuIC (i.e. use of FLBV-rPrP) reaction substrates, suggests 
a pivotal role for this component in both the methods (Orrù et al. 2015b; Camacho et 
al. 2019).  
However, the idea that the substrate is the only major factor shaping PMCA and RT-
QuIC in vitro amplification of human prions might be simplistic as there is evidence 
indicating that the two in vitro reactions utilize their respective substrate in different 
ways. Specifically, in RT-QuIC sequence homology between seed and substrate is 
not mandatory to obtain amplification, while in PMCA, it is a key factor influencing the 
efficiency of amplification (Barria 2014; Jones et al. 2008; Camacho et al. 2019). 
Therefore, other factors should be taken into account to attempt a mechanistic 
description of the observed differential amplification preferences of PMCA and RT-
QuIC for vCJD or sCJD. Among these factors are the molecular characteristics of the 
seeds. Indeed, sCJD and vCJD can be discriminated, at a molecular level, based on 
the different glycotype of the respective PrPres. The PrPres found in sCJD, irrespective 
of being type 1 or type 2, typically presents, upon standardized WB analysis,  a 
relative over-representation of the monoglycosylated form (termed pattern A) while 
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the PrPres found in the vCJD cases analysed so far is typically of type 2 and shows a 
relative over-representation of the diglycosylated form (termed pattern B) (Head 
2013). The latter pattern is also typical of the classical BSE (Hill et al. 1997; Bruce et 
al. 1997), while it has been suggested that the former (i.e. pattern A) characterizes 
rarer, atypical forms of BSE (Casalone et al. 2004; Biacabe et al. 2004). Interestingly, 
PMCA amplification preference for vCJD over sCJD is mirrored by its preference for 
classical BSE over the atypical forms of BSE (Barria et al. 2014). Remarkably, several 
RT-QuIC set-ups (i.e. those using full-length and truncated forms of hamster rPrP or 
FLHu-rPrP) show a symmetrical trend, being more efficient than PMCA at amplifying 
sCJD and the atypical forms of BSE  (Levavasseur et al. 2017; Masujin et al. 2016). 
Collectively, this evidence appears to suggest that PMCA preferentially amplifies 
pattern B seeds while RT-QuIC preferentially amplifies pattern A. This observation 
allows speculation regarding the role of seed glycosylation in shaping prion in vitro 
amplification. Specifically, it appears that less heavily glycosylated seeds (i.e. pattern 
A) are amplified more efficiently by an unglycosylated substrate (i.e. a rPrP or 
deglycosylated  PrPC as in Camacho et al., 2019), while more heavily glycosylated 
seeds (i.e. pattern B) are amplified more efficiently by a glycosylated substrate (i.e. 
the typical PMCA substrate). As above-mentioned, results presented in Chapter 3, 
show for the first time a comparative analysis of PMCA and RT-QuIC reaction kinetics 
when amplifying the same seed. Notably, both the reaction kinetics show a sigmoidal 
shape, with an initial lag phase followed by a rise to reach a plateau phase, that is 
typical of protein misfolding and aggregation. However, as discussed in Chapter 3, 
the systematic comparison of PMCA and RT-QuIC reaction kinetics is limited by the 
technical differences between the detection systems of the two methods as well as 
by the biochemical characteristics of the substrates used. Nonetheless, the 
identification of the sCJD subtype VV2 as benchmark seed amplified by both 
methods, offers the possibility to further compare the two methods and possibly 
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elucidate the role of seed glycosylation and substrate modifications in PMCA and RT-
QuIC. 
PMCA and RT-QuIC also differ in regard to the characteristics of the respective 
amplification products. The experimental inoculation of the products of PMCA reaction 
seeded with animal and human prion strains, suggest that the material generated in 
vitro is able to reproduce the disease phenotype of the original prion strain (Castilla 
et al. 2008; Cali et al. 2019). In contrast, Scrapie-seeded RT-QuIC reaction products 
do not appear to be infectious upon experimental inoculation into animal models 
(Groveman et al. 2017). Moreover, the amplification by PMCA of vCJD and sCJD 
samples, generate products, which, upon PK digestion and standardized WB 
analysis, present with the same PrPres type of the original seed (Jones et al. 2008; 
Barria et al. 2014). Conversely, it is not clear, at this point in time, to what extent the 
characteristics of the original seed are retained in the RT-QuIC reaction products 
(Sano et al. 2014; Piconi et al. 2019). The results presented in Chapter 4 suggest that 
the RT-QuIC set-up using the FLHa-rPrP, when seeded with sCJD 10%BH or CSF 
samples, generates products that resemble naturally occurring PrPSc in being 
resistant to limited PK treatment. Nonetheless, no sCJD subtype-specific differences 
in terms of the electrophoretic mobility, abundance or extent of the PK resistant core 
were observed via the epitope mapping analysis of the protease resistant products 
presented in the same Chapter (Piconi et al. 2019). In this framework of evidence, it 
is plausible that the above-mentioned differences in PMCA and RT-QuIC reactions 
products might be explained, at least in part, by the different composition of PMCA 
and RT-QuIC reaction environments. On the one hand, PMCA reaction environment 
seems to resemble the cellular environment more closely and, therefore, allows 
PMCA to more accurately model the complete set of properties (i.e. biochemical 
properties, infectivity, species barrier, strain phenomenon) that the natural prion 
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replication mechanism reproduces each time prions replicate. On the other hand, the 
RT-QuIC reaction environment is much simpler and appears to be a distillation of the 
basic elements (i.e. seed, substrate, energy input) needed for reproducing prion 
replication process. It is also to be noted that the RT-QuIC reaction environment, in 
spite of being seeded with brain material, might not contains, at an high enough 
concentration, the cofactors known to be needed in order to produce infectious 
preparations in vitro from rPrP (Noble and Supattapone 2015)  In this way, RT-QuIC 
appears to model basic functional properties of prions, specifically the ability to induce 
the misfolding of homologous proteins (i.e. seeding activity). The idea that the prion 
defining properties, such as seeding activity and infectivity, may exist independently 
from one another is at the basis of the deployment of the prion concept to proteins 
other than PrP. The successful design and deployment of RT-QuIC set-ups based on 
prion-like proteins (i.e. proteins characterized by certain prion defining properties) 
appears to sustain this idea (Fairfoul et al. 2016; Groveman et al. 2018; Saijo et al. 
2017). 
6.3 Diagnostic application of human prion amplification in cell-free systems 
The diagnosis of sCJD has significantly improved in the last 20 years, thanks to 
technological advancements in brain imaging, the development of biomarker assays 
including the CSF analysis by RT-QuIC and improved knowledge of the disease 
phenotypic spectrum (reviewed in Zerr and Parchi, 2018). However, the post mortem 
examination of brain tissue remains the gold standard method for confirming a sCJD 
diagnosis as well as for the identification of sCJD subtypes. In this context, the 
development of diagnostic tests based on the analysis of body fluid more accessible 
than CSF and/or able to discriminate sCJD subtypes intra vitam, represent desirable 
further improvements. Although no treatment is currently available for sCJD, the 
definition of the sCJD subtype intra vitam would inform patient and caregivers more 
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precisely on the disease outlook, as well as aid the stratification of patients upon 
recruitment in future clinical trials. The hypothesis investigated in Chapter 4 
addresses the discrimination of sCJD subtypes by systematically investigating the 
resistance to limited proteolysis and the length of the PK resistant fragments of the 
RT-QuIC products generated when seeding the reaction with brain or CSF samples 
of the six most common sCJD subtypes. The results showed that, for the 
characteristics investigated, no subtype-specific differences were apparent. As 
discussed in Chapter 4, this evidence allows speculation that sCJD brain and CSF 
samples may share a component that induces the misfolding and aggregation of the 
rPrP substrate into structurally similar aggregates. Indeed there is evidence indicating 
that sCJD CSF samples may contain disease-specific PrP aggregates (Bieschke et 
al. 2000). However, these aggregates have not been further characterized and, 
therefore, cannot be unequivocally related to the PrPSc found in sCJD brain samples. 
An alternative explanation for the results obtained might be that the highly ordered 
conformational landscape of the purified FLHa-rPrP substrate does not allow the 
selection of subtype-specific conformational pathways within the time frame of the 
reaction kinetics.  Applying the RT-QuIC product analysis method developed here to 
the products of the second generation RT-QuIC (Orrù et al. 2015a), might possibly 
address this latter point. In fact, second generation RT-QuIC uses 90-231Ha-rPrP 
instead of the FLHa-rPrP as reaction substrate and there is evidence indicating that, 
the shape of the second generation RT-QuIC reaction kinetic seeded with sCJD CSF 
samples are subtype-specific (Foutz et al. 2017) therefore might represent structural 
differences in the generated aggregates.  
The possibility of using olfactory mucosa (OM) samples from sCJD patients to seed 
RT-QuIC is a promising alternative or complementary option to CSF. OM can be 
sampled with relatively non-invasive methods (i.e. nasal brush or swab) and it has 
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been shown that its analysis via RT-QuIC has diagnostic value for sCJD (Bongianni 
et al. 2017; Orrù et al. 2014). The hypothesis addressed in Chapter 5, instead, 
represents a first step in extending RT-QuIC diagnostic applicability to urine, one of 
the more easily sampled human biological fluids. The results obtained showed for the 
first time that the application of specifically designed sample preparation procedures, 
allow to observe seeding activity in sCJD urine samples by RT-QuIC. However, the 
levels of specificity and sensitivity achieved were not high enough to confer reliable 
diagnostic power to the assay. While these data can be considered a proof of concept, 
it is important to remark that the seeding activity observed in the sCJD urine samples 
examined should not raise public health concerns. In fact, it cannot be unequivocally 
assigned to the presence of a prion-specific seeding active component. Moreover, 
even in the case that a prion-specific seeding active component is responsible for the 
observed seeding activity in sCJD urine, it would be present at very low concentration 
and very likely be unable to transmit the disease. Indeed, as already shown by other 
authors, experimental inoculation of sCJD urine samples does not elicit disease 
transmission (Brown et al. 1994; Notari et al. 2012). 
Nonetheless, these data demands further investigation to ascertain the presence or 
the complete absence of seeding activity in sCJD urine would be valuable information. 
On the one hand, the complete absence of prion-specific seeding activity in sCJD 
urine would further refine the description of this disease and highlight another 
difference with vCJD. Indeed, it has been shown that vCJD urine samples can seed 
the PMCA reaction (Moda et al. 2014) and, therefore, be discriminated from non-CJD 
urine samples. On the other hand, the reliable detection of seeding activity in sCJD 
urine may represent a further reduction of the invasiveness of the diagnostic sampling 
for the most common form of human PrD.  
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6.4 General conclusions 
The in vitro human prion amplification by PMCA and RT-QuIC represents an 
invaluable tool for prion research and clinical diagnosis of PrD. Through the research 
performed for this thesis, it has been possible to: (i) systematically evaluate PMCA 
and RT-QuIC amplification of vCJD and sCJD, (ii) compare for the first time the 
kinetics of the two reactions, (iii) investigate the possible discrimination of sCJD 
subtype by RT-QuIC, and (iv) assess the possibility of generating a sCJD diagnostic 
test based on the RT-QuIC analysis of patient urine samples. In summary, the work 
presented in this thesis provide insights into the molecular mechanisms of the in vitro 
amplification of human prions and highlights its diagnostic applicability.  
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Appendix I  
Part of the data presented in this thesis were published in a scientific journal. The 
article is reproduced in this appendix. 
 
Piconi G., Peden A.H., Barria M.A., Green A.J.E. (2019) Epitope mapping of the 
protease resistant products of RT-QuIC does not allow the discrimination of sCJD 





























































































































S1 Figure: BH-RT-QuIC reaction products treated with increasing (continued on next page) 
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(continued) concentrations of PK and analysed by WB with panel of six commercially available 
mAbs. 
Results from each individual mAb are displayed in columns, from left to right, 12B2 1:10000, 3F4 
1:10000, 6H4 1:1000, SAF70 1:1000, 8H4 1:2000, 94B4 1:1000. This order mirrors the position on the 
FLHa-rPrP primary sequence of each mAbs epitope from the N- to the C-terminal. For each blot, Lanes 
(1–6): products of RT-QuIC reactions seeded with sCJD 10%BH subtypes MM1, MM2c, MV1, MV2, VV1, 
VV2, respectively. Lane (7): products of reaction seeded with non-CJD 10%BH. Lane 8: unseeded 
reaction products. Lane (9): RT-QuIC untreated reaction mixture. Row (A) RT-QuIC reaction products 
before proteolytic treatment, row (B) RT-QuIC reaction products treated with PK 10 μg/mL, row (C) PK 





Appendix II  
PMCA raw data set 
 
Figure II.1 vCJD seeded PMCA raw data set 
Figure A, B and C: WBs for the detection of PMCA reaction products. The identification of the sample is 
shown on top of each WB picture. The dilution factor (seed-into-substrate) used is indicated below the 
sample name. For each sample two technical replicates were run in each PMCA experiment. F: Frozen 
sample; S: Sonicated sample. The S/F values calculated on each pair of S and F samples are indicated 
at the bottom of each WB picture, in correspondence with the signals analysed. WB immunodetection 
was with mAb 3F4. MM: molecular weight marker; kDa: kilodalton. Figure D: Graphical representation of 
the mean average S/F ratios. Each data point represents the mean average of the results of the 
densitometric analysis performed on the WBs for the detection of PMCA reaction products of each 





Figure II.2 sCJD subtype VV2 seeded PMCA raw data set 
Figure A, B and C: WBs for the detection of PMCA reaction products. The identification of the sample is 
shown on top of each WB picture. The dilution factor (seed-into-substrate) used is indicated below the 
sample name. For each sample two technical replicates were run in each PMCA experiment. F: Frozen 
sample; S: Sonicated sample. The S/F values calculated on each pair of S and F samples are indicated 
at the bottom of each WB picture, in correspondence with the signals analysed. WB immunodetection 
was with mAb 3F4. MM: molecular weight marker; kDa: kilodalton. Figure D: Graphical representation of 
the mean average S/F ratios. Each data point represents the mean average of the results of the 
densitometric analysis performed on the WBs for the detection of PMCA reaction products of each 







Figure II.3 sCJD subtype MM1 seeded PMCA raw data set 
Figure A, B and C: WBs for the detection of PMCA reaction products. The identification of the sample is 
shown on top of each WB picture. The dilution factor (seed-into-substrate) used is indicated below the 
sample name. For each sample two technical replicates were run in each PMCA experiment. F: Frozen 
sample; S: Sonicated sample. The S/F values calculated on each pair of S and F samples are indicated 
at the bottom of each WB picture, in correspondence with the signals analysed. WB immunodetection 
was with mAb 3F4. MM: molecular weight marker; kDa: kilodalton. Figure D: Graphical representation of 
the mean average S/F ratios. Each data point represents the mean average of the results of the 
densitometric analysis performed on the WBs for the detection of PMCA reaction products of each 








Figure II.4 sCJD subtype MV1 seeded PMCA raw data set 
Figure A, B and C: WBs for the detection of PMCA reaction products. The identification of the sample is 
shown on top of each WB picture. The dilution factor (seed-into-substrate) used is indicated below the 
sample name. For each sample two technical replicates were run in each PMCA experiment. F: Frozen 
sample; S: Sonicated sample. The S/F values calculated on each pair of S and F samples are indicated 
at the bottom of each WB picture, in correspondence with the signals analysed. WB immunodetection 
was with mAb 3F4. MM: molecular weight marker; kDa: kilodalton. Figure D: Graphical representation of 
the mean average S/F ratios. Each data point represents the mean average of the results of the 
densitometric analysis performed on the WBs for the detection of PMCA reaction products of each 






Figure II.5 sCJD subtype MM2c seeded PMCA raw data set 
Figure A, B and C: WBs for the detection of PMCA reaction products. The identification of the sample is 
shown on top of each WB picture. The dilution factor (seed-into-substrate) used is indicated below the 
sample name. For each sample two technical replicates were run in each PMCA experiment. F: Frozen 
sample; S: Sonicated sample. The S/F values calculated on each pair of S and F samples are indicated 
at the bottom of each WB picture, in correspondence with the signals analysed. WB immunodetection 
was with mAb 3F4. MM: molecular weight marker; kDa: kilodalton. Figure D: Graphical representation of 
the mean average S/F ratios. Each data point represents the mean average of the results of the 
densitometric analysis performed on the WBs for the detection of PMCA reaction products of each 






Figure II.6 sCJD subtype MV2 seeded PMCA raw data set 
Figure A, B and C: WBs for the detection of PMCA reaction products. The identification of the sample is 
shown on top of each WB picture. The dilution factor (seed-into-substrate) used is indicated below the 
sample name. For each sample two technical replicates were run in each PMCA experiment. F: Frozen 
sample; S: Sonicated sample. The S/F values calculated on each pair of S and F samples are indicated 
at the bottom of each WB picture, in correspondence with the signals analysed. WB immunodetection 
was with mAb 3F4. MM: molecular weight marker; kDa: kilodalton. Figure D: Graphical representation of 
the mean average S/F ratios. Each data point represents the mean average of the results of the 
densitometric analysis performed on the WBs for the detection of PMCA reaction products of each 







Figure II.7 sCJD subtype MV2 seeded PMCA raw data set 
Figure A, B and C: WBs for the detection of PMCA reaction products. The identification of the sample is 
shown on top of each WB picture. The dilution factor (seed-into-substrate) used is indicated below the 
sample name. For each sample two technical replicates were run in each PMCA experiment. F: Frozen 
sample; S: Sonicated sample. The S/F values calculated on each pair of S and F samples are indicated 
at the bottom of each WB picture, in correspondence with the signals analysed. WB immunodetection 
was with mAb 3F4. MM: molecular weight marker; kDa: kilodalton. Figure D: Graphical representation of 
the mean average S/F ratios. Each data point represents the mean average of the results of the 
densitometric analysis performed on the WBs for the detection of PMCA reaction products of each 






Figure II.8 sCJD subtype BH1VV2P PMCA kinetics study 
In the box: WBs for the analysis of PMCA reaction kinetics. PMCA reaction seeded with BH1VV2P at 
dilution 1x10-2 was sampled in triplicates at defined time interval (i.e. t1, 6.5, 24, 30, 48, 54.5). F: Frozen sample; 
S: Sonicated sample. The S/F values calculated on each pair of S and F samples are indicated at the 
bottom of each WB picture, in correspondence with the signals analysed. WB immunodetection was with 
mAb 3F4. MM: molecular weight marker; kDa: kilodalton. Below the box: graph summarizing PMCA 







Figure II.9 sCJD subtype BH3VV2P PMCA kinetics study 
In the box: WBs for the analysis of PMCA reaction kinetics. PMCA reaction seeded with BH1VV2P at 
dilution 1x10-2 was sampled in triplicates at defined time interval (i.e. t1, 6.5, 24, 30, 48, 54.5). F: Frozen sample; 
S: Sonicated sample. The S/F values calculated on each pair of S and F samples are indicated at the 
bottom of each WB picture, in correspondence with the signals analysed. WB immunodetection was with 
mAb 3F4. MM: molecular weight marker; kDa: kilodalton. Below the box: graph summarizing PMCA 





Appendix III  
Raw data used for the evaluation of the PrPres levels in the 10%BHs 
 
 
Figure III.1 WB for the evaluation of the PrPres levels in the vCJD 10%BH 
WBs for the evaluation of the PrPres levels in the vCJD 10%BH. WB were performed as described in 
Section 2.4.1. The volume of PK treated 10%BH that was loaded onto the gel is indicated on top of each 
WB picture, along with the amount of FLHa-rPrP used as standard. The identification of the sample is 
shown at the bottom of each WB picture. WB immunodetection was with mAb 3F4. MM: molecular weight 





Figure III.2 WB for the evaluation of the PrPres levels in the sCJD MM1 10%BH  
WBs for the evaluation of the PrPres levels in the vCJD 10%BH. WB were performed as described in 
Section 2.4.1. The volume of PK treated 10%BH that was loaded onto the gel is indicated on top of each 
WB picture, along with the amount of FLHa-rPrP used as standard. The identification of the sample is 
shown at the bottom of each WB picture. WB immunodetection was with mAb 3F4. MM: molecular weight 










Figure III.3 WB for the evaluation of the PrPres levels in the sCJD MV1 10%BH 
WBs for the evaluation of the PrPres levels in the vCJD 10%BH. WB were performed as described in 
Section 2.4.1. The volume of PK treated 10%BH that was loaded onto the gel is indicated on top of each 
WB picture, along with the amount of FLHa-rPrP used as standard. The identification of the sample is 
shown at the bottom of each WB picture. WB immunodetection was with mAb 3F4. MM: molecular weight 






Figure III.4 WB for the evaluation of the PrPres levels in the sCJD MM2c 10%BH  
WBs for the evaluation of the PrPres levels in the vCJD 10%BH. WB were performed as described in 
Section 2.4.1. The volume of PK treated 10%BH that was loaded onto the gel is indicated on top of each 
WB picture, along with the amount of FLHa-rPrP used as standard. The identification of the sample is 
shown at the bottom of each WB picture. WB immunodetection was with mAb 3F4. MM: molecular weight 








Figure III.5 WB for the evaluation of the PrPres levels in the sCJD MV2 10%BH 
WBs for the evaluation of the PrPres levels in the vCJD 10%BH. WB were performed as described in 
Section 2.4.1. The volume of PK treated 10%BH that was loaded onto the gel is indicated on top of each 
WB picture, along with the amount of FLHa-rPrP used as standard. The identification of the sample is 
shown at the bottom of each WB picture. WB immunodetection was with mAb 3F4. MM: molecular weight 








Figure III.6 WB for the evaluation of the PrPres levels in the sCJD VV1 10%BH 
WBs for the evaluation of the PrPres levels in the vCJD 10%BH. WB were performed as described in 
Section 2.4.1. The volume of PK treated 10%BH that was loaded onto the gel is indicated on top of each 
WB picture, along with the amount of FLHa-rPrP used as standard. The identification of the sample is 
shown at the bottom of each WB picture. WB immunodetection was with mAb 3F4. MM: molecular weight 








Figure III.7 WB for the evaluation of the PrPres levels in the sCJD VV2 10%BH 
WBs for the evaluation of the PrPres levels in the vCJD 10%BH. WB were performed as described in 
Section 2.4.1. The volume of PK treated 10%BH that was loaded onto the gel is indicated on top of each 
WB picture, along with the amount of FLHa-rPrP used as standard. The identification of the sample is 
shown at the bottom of each WB picture. WB immunodetection was with mAb 3F4. MM: molecular weight 
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